

Review

Does the ERBB/EGF Signaling Network Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?

Niusha Raeesian ^{1,2} and David J. Riese II ^{1,3,*} 

¹ Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA; niusha.raeesian@gmail.com

² Program in Molecular Biotechnology, Department of Applied Biosciences and Process Engineering, Anhalt University of Applied Sciences, 06366 Köthen, Germany

³ Cancer Biology and Immunology Research Program, O'Neal Comprehensive Cancer Center, Heersink College of Medicine, University of Alabama-Birmingham, Birmingham, AL 35233, USA

* Correspondence: djr0009@auburn.edu

Abstract

Uveal melanomas (UMs) metastasize at a high frequency, and metastatic UMs are associated with very poor clinical outcomes. Consequently, there is considerable interest in the genetics and biochemistry of UM and in how these insights may lead to novel and effective approaches to treating it. This work reviews the biology and pharmacotherapy of UM. It also summarizes signaling by the network comprising ERBB receptor tyrosine kinases and EGF family peptide growth factors, including mechanisms of crosstalk with G protein-coupled receptors. Next, this work discusses signaling changes that appear to drive UM, particularly increased signaling by the CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ pathway. Finally, this work suggests that some of the signaling events that drive UM may be the consequence of crosstalk between the CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ pathway and the ERBB/EGF signaling network. Thus, this work proposes that the ERBB/EGF signaling network may be a novel therapeutic target for UM.

Keywords: uveal melanoma; targeted therapy; signal transduction; Galphaq; Galpha11; PI3K/AKT/mTOR; RAS-MAPK; GPCR-EGFR crosstalk; ERBB signaling

1. Introduction to Uveal Melanoma

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, accounting for approximately 4–5% of all melanomas. Its worldwide incidence is reported to range from 4 to 7 cases per million individuals annually [1–12]. UM consists of any malignant lesion derived from melanocytes of the uveal tissues (choroid, ciliary body, and iris). UM most frequently arises in choroid tissues (90%) and less frequently in the ciliary body (6%) and iris (4%) [3,10,13–17].

UM typically presents in adulthood, with a peak incidence around age 60 [3,13,15]. The goals of UM treatment are to prevent metastatic spread and conserve the eye and vision [3,14,18]. As noted elsewhere in this review, the primary tumor treatment options are considered relatively effective. Nonetheless, the prognosis for UM patients is often poor, as UM frequently metastasizes to the liver, presumably before or during the treatment of the primary tumor. This challenge is exacerbated by the lack of effective targeted therapies for metastatic UM [3,5,10,12,16,17,19–30]. In fact, the 2025 NCCN guidelines indicate that the preferred therapy for metastatic UM is a clinical trial [3,31].



Academic Editor: Dirk Geerts

Received: 28 June 2026

Revised: 21 July 2026

Accepted: 21 July 2026

Published: 23 July 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article

distributed under the terms and

conditions of the [Creative Commons](https://creativecommons.org/licenses/by/4.0/)

[Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

UM is more common in Caucasian populations, particularly at higher latitudes, and among individuals with light-colored skin and irises, suggesting that solar ultraviolet light exposure contributes to its pathogenesis [1,5,6,16,32,33]. Thus, it is somewhat surprising that UM most frequently arises in choroid tissues, as these tissues are relatively protected from sunlight [10,34,35]. Likewise, UM does not typically exhibit the same genetic changes as cutaneous skin melanoma (CM), which is also strongly associated with sunlight exposure [2,3,5,10,29,36–39]. Therefore, targeted therapies for CM do not appear to be effective against UM. Given the limited efficacy of current targeted approaches for metastatic UM, identifying additional signaling mechanisms that contribute to tumor progression remains a major priority. In this review, we will discuss why the signaling network comprising ERBB receptor tyrosine kinases and Epidermal Growth Factor (EGF) family peptide hormones may drive UM and serve as a target for UM therapy.

2. Treatment of Uveal Melanoma

The typical treatment for primary UM includes radiotherapy (either plaque brachytherapy or external radiation therapy), photocoagulation, transpupillary thermotherapy, and various forms of tumor removal, such as transscleral resection, endoresection, and removal of the entire eye (enucleation). Thus, UM treatment is commonly associated with visual handicap or facial disfigurement [10,17,25,40]. The treatment of primary UM is typically effective, as relatively few patients experience recurrence at the primary tumor site. Nonetheless, approximately 50% of UM patients eventually develop metastatic disease. Roughly 90% of metastatic melanomas target the liver, whereas the lung and bone are targeted to a lesser extent [2,3,8,10,12,20,25,26,29,41].

Metastatic UM appears to arise from hematogenous spread of micrometastases before or during treatment of the primary tumor; even enucleation or exenteration (removal of the eye and surrounding tissues) has little effect on the progression to metastatic disease [3,5,7,16–18,42–46]. Metastatic UM is typically fatal, with a median overall survival of 4 to 15 months [2,3,7,8,10,17,23–26,29,46,47]. However, the median time to progression to metastatic UM is measured in years [17,19,20,28,48], as the mortality rate at 10–15 years after diagnosis of the primary tumor is approximately 40–50% [7,17,19,20,48]. The long latency of progression and mortality suggests that the latent micrometastases must acquire additional genetic changes (relative to the primary tumor) to become clinically relevant.

Circulating tumor DNA (ctDNA) is a biomarker of UM progression to metastatic disease [17,49–51]. Therefore, strategies for treating metastatic UM should be reserved for patients with detectable metastases or ctDNA [12,25,52,53], as the benefits of therapy are more likely to outweigh any adverse effects in these patients. Similarly, given the long latency of metastatic UM, cytotoxic agents are unlikely to be suitable for preventing the progression of UM micrometastases.

Unfortunately, as noted earlier, there is no effective standard treatment for metastatic UM [3,10,16,30,31]. Nonetheless, several advances in treatment paradigms have been made, particularly those aimed at reducing tumor cell immune evasion [3,12,16].

Immune checkpoint inhibitors (ICIs), including antibodies against PD-1 (e.g., pembrolizumab, nivolumab), PD-L1 (e.g., atezolizumab), and CTLA-4 (e.g., ipilimumab), are effective against CM and other immunogenic tumors [3,54–72]. Unfortunately, single ICI agents exhibit limited therapeutic efficacy against metastatic UM. Likewise, combinations of ICIs have elicited surprisingly modest responses, presumably due to the relatively low mutational and neoantigen burden in these tumor cells, particularly those harboring wild-type *MBD4* alleles, which encode an enzyme that participates in DNA base excision repair [3,6,16,31,39,73–83]. Thus, future experimentation may identify metastatic UM sub-

types that exhibit more robust responses to combinations of ICIs or to agents effective in combination with ICIs.

Tumor-infiltrating lymphocyte (TIL) therapy has shown promising activity against metastatic UM [3,84]. However, this approach requires preparing TILs for each patient, which is expensive and limits scalability [3,85]. Nonetheless, given that TILs appear to be more effective than ipilimumab against metastatic CM [85–87], further investigation of TIL therapy may be warranted, particularly if TIL therapy can overcome the limitations of ICI effectiveness in low-mutational-burden tumors. Optimism regarding TIL therapy is tempered by the observation that TIL therapy is typically effective only in patients with a long history of recurrence. Indeed, this limitation suggests that innovation in other treatment modalities is strongly warranted.

Uveal melanomas and CMs commonly overexpress gp100, a 100 kDa glycosylated transmembrane protein involved in melanosome maturation [88,89]. Moreover, gp100 is a target for anti-CM TILs and anti-CM vaccines [88,90–92]. Consequently, agents targeting gp100 have been extensively studied as potential anti-UM therapies. Tebentafusp is an ImmTAC (immunomobilizing monoclonal T-cell receptor targeting cancer) that recognizes a gp100 peptide in the context of a specific human leukocyte antigen (HLA-A*0201) on the surface of tumor cells. Tebentafusp then recruits and activates T lymphocytes, ultimately forming a “lytic immune synapse” between the target tumor cell and the cytotoxic T lymphocyte [3,88,93].

Some of the earliest data emerging from the pivotal tebentafusp phase III clinical trial (NCT03070392 [94]) reported that HLA-A*0201 metastatic UM patients treated with tebentafusp exhibited 73% overall survival at 1 year, whereas control patients treated with the investigators’ choice of therapy (pembrolizumab, dacarbazine, or ipilimumab) showed 59% overall survival at 1 year. Likewise, 6-month progression-free survival was higher in the tebentafusp group (31%) than in the control group (19%) [93]. Thus, in January 2022, tebentafusp was granted Breakthrough Therapy designation by the United States Food and Drug Administration [6,10,16,29,39,95–97].

Additional data from NCT03070392 indicated that the median overall survival of HLA-A*0201 metastatic UM patients was 21.6 months in the tebentafusp group and 16.9 months in the control group (0.68 hazard ratio [95% confidence interval of 0.54–0.87]). The three-year survival was 27% in the tebentafusp group and 18% in the control group. By approximately 64 months, all control patients had died, while approximately 15% of the patients in the tebentafusp group were alive [94,96]. This modest effect on survival highlights the need for additional innovation in metastatic UM therapy, particularly since only approximately 50% of Caucasians and fewer Hispanics and African Americans are HLA-A*0201 positive [3,16,17,88,97,98].

Commonly mutated genes in UMs include *BAP1*, *GNAQ*, and *GNA11*. *BAP1* (BRCA1 Associated Protein 1) encodes a deubiquitinase (DUB) that regulates target protein function through cleavage or modification of ubiquitin chains conjugated to the target protein. *BAP1* appears to function as a tumor suppressor in UM, suggesting that *BAP1* inhibitors are not suitable candidates for UM therapy [5,6,10,12,16,17,29,99]. *GNAQ* and *GNA11* encode alpha subunits of heterotrimeric G proteins that couple heptahelical G protein-coupled receptors (GPCRs) to downstream intracellular signaling events. Dominant mutations in *GNAQ* and *GNA11* appear to drive UM by disrupting GTP hydrolysis by $G_{\alpha q}$ or $G_{\alpha 11}$ and prolonging GTP-dependent $G_{\alpha q}/G_{\alpha 11}$ signaling [5,6,10,12,29]. Thus, potent small-molecule inhibitors of $G_{\alpha q}/G_{\alpha 11}$ have been identified. Two such inhibitors are complex natural products with very low translational potential [100–102]. Synthetic small-molecule inhibitors of $G_{\alpha q}/G_{\alpha 11}$ have been used in structure-activity relationship and mechanistic studies [100,103–105]. Theoretically, topical administration of a $G_{\alpha q}/G_{\alpha 11}$ inhibitor could

be used to treat primary UM. However, it is unlikely that this approach would be more effective than current treatment modalities. Moreover, because of the widespread importance of $G_{\alpha q}/G_{\alpha 11}$ signaling, systemic administration of a $G_{\alpha q}/G_{\alpha 11}$ inhibitor to prevent or treat metastatic UM causes severe on-target, off-tumor toxicities [106,107]. However, DYP688 [108], a conjugate of the $G_{\alpha q}/G_{\alpha 11}$ inhibitor SDZ475 (FR900359) [101] with an anti-gp100 monoclonal antibody, has shown promising preliminary activity in a phase I clinical trial in patients with metastatic UM [107].

Consequently, the identification of apparent UM driver mutations in *BAP1*, *GNAQ*, and *GNA11* has not yet yielded strategies for preventing or treating metastatic UMs [5,6,10,16,17,29,31]. Indeed, as noted elsewhere, approximately 90% of primary UMs possess a driver mutation in *GNAQ* or *GNA11*. In contrast, only 50% of primary UMs undergo metastasis. Thus, neither *GNAQ* nor *GNA11* mutations are sufficient to drive metastatic disease. Thus, the goal of this work is to identify additional molecular changes that drive UM metastases and may serve as better targets for therapeutic intervention. However, combinations of targeted chemotherapeutic agents with disparate mechanisms of action can exhibit unacceptable toxicity. Moreover, resistance can appear rapidly in tumors that initially respond to such combinations. Hence, the challenge in UM drug discovery appears to be in identifying a signaling nexus that enables activation of multiple signaling pathways in UM and allows a single targeted agent to simultaneously engage multiple signaling events. Here, we propose such a nexus for oncogenic signaling in UM.

3. Elevated ERBB Receptor Signaling Drives Many Malignancies

The Epidermal Growth Factor Receptor (EGFR/ERBB1) is a receptor tyrosine kinase (RTK) that is closely related to three other ERBB receptor tyrosine kinases (ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4). Ligands for ERBB receptors include amphiregulin, betacellulin, EGF, epigen, epiregulin, heparin-binding EGF-like growth factor, neuregulin isoforms, and transforming growth factor alpha. ERBB ligands are initially expressed as transmembrane precursor proteins that must be cleaved to enable the soluble form of the ligand to bind the extracellular region of the cognate receptor [109–122].

Elevated signaling by the ERBB/EGF network drives many human malignancies [110,112–115,117,119–146]. These mechanistic insights have been translated into clinical practice, as the United States Food and Drug Administration has approved numerous ERBB small-molecule tyrosine kinase inhibitors (TKIs) as cancer therapeutics, including afatinib [147–152], dacomitinib [123,147,148,150,151], erlotinib [123,128,136,147,153], gefitinib [123,128,136,147,153], lapatinib [154–158], lazertinib [123,147,159,160], neratinib [123,155,161], osimertinib [123,128,136,147,162,163], sevabertinib [164–170], sunvozertinib [147,163,171–173], tucatinib [157,174–176], and zongertinib [165–168,170,173,177]. Monoclonal antibody drugs against ERBB receptors include amivantamab [129,151,159,160,163,171], cetuximab [148,178–183], margetuximab [184,185], necitumumab [181–183], panitumumab [180–182,186], pertuzumab [145,185,187], and trastuzumab [145,146,154,174,186]. Finally, trastuzumab also serves as a targeting moiety for cytotoxic drug conjugates [129,133,145,165–168,187].

The large number of human malignancies driven by elevated ERBB receptor signaling appears to reflect the mechanistic complexity of the ERBB/EGF signaling network (Figure 1). Ligand binding stabilizes the ERBB receptor extracellular domains in the open conformation, exposing two dimerization motifs and enabling symmetrical dimerization of the receptor extracellular domains. Because a small fraction of EGFR that is present on the cell surface exists in the conformation that is competent for dimerization, overexpression of EGFR (and other ERBB RTKs) can cause ligand-independent symmetrical dimerization of the receptor extracellular domain.




Figure 1. EGF Binding and EGFR Dimerization. Figure 1 Legend: This figure illustrates the mechanism by which EGF binding stimulates EGFR dimerization. This mechanism is shared by ERBB3, ERBB4, and their ligands. ERBB2 has no ligands and exists exclusively in the open conformation. Mechanistic details are described in the text. Created in BioRender. Riese, D. (2026) <https://BioRender.com/gcswiuw> (accessed on 19 July 2026) [188].

In both ligand-dependent and -independent signaling, this symmetrical dimerization of the ERBB extracellular domains is accompanied by asymmetrical dimerization of the ERBB intracellular domains (Figure 2); the carboxyl-terminal (“C”) region of the kinase domain of the regulatory/substrate monomer binds to the amino-terminal (“N”) region of the catalytic monomer. This alters the conformation of the catalytic monomer, enabling its tyrosine kinase activity. The catalytic monomer phosphorylates tyrosine residues that reside downstream of the kinase domain of the regulatory/substrate monomer. The region containing the sites of tyrosine phosphorylation is conformationally labile, thereby enabling the phosphorylation of multiple tyrosine residues within it. In sum, within an ERBB receptor dimer, the kinase domain of one ERBB monomer phosphorylates multiple tyrosine residues of the other ERBB monomer. Therefore, mechanistically, ERBB receptors do not undergo autophosphorylation; instead, transphosphorylation occurs within the dimer. As noted earlier, each ERBB receptor contains multiple tyrosine phosphorylation sites, each of which can bind distinct effector proteins via their SH2 or PTB domains. Thus, ERBB receptor phosphorylation activates numerous signaling pathways and biological responses, and differences in the sites of tyrosine phosphorylation on a given ERBB family receptor may confer signaling specificity [109,114,122,127,132,137,189].




Figure 2. ERBB Receptor Trans-Phosphorylation. Figure 2 Legend: This figure illustrates the mechanism by which ERBB receptor dimerization causes receptor trans-phosphorylation. This mechanism is shared by ERBB receptor homo- and heterodimers. Mechanistic details are described in the text. Created in BioRender. Riese, D. (2026) <https://BioRender.com/xj19yq8> (accessed on 19 July 2026) [190].

Phosphorylation site specificity appears to be conferred by differential juxtaposition of ERBB monomers within the dimer; differences in monomer juxtaposition are likely to alter the access of tyrosine residues on one receptor monomer to the kinase domain of the other. This specificity of ERBB dimer conformations appears to underlie many of the functional differences among the various ligands for a particular ERBB receptor [119,139,191–198].

Specificity also arises through heterodimerization by ERBB family receptors. This heterodimerization enables ligand-dependent signaling by ERBB2, which does not bind any EGF family member; heterodimerization also facilitates signaling by ERBB3, which possesses little tyrosine kinase activity. Hence, ligand-binding to EGFR, ERBB3, or ERBB4 may also elicit signaling by the other three ERBB receptors. Heterodimerization greatly diversifies ERBB receptor signaling, as the phosphorylated tyrosine residues on each of the four ERBB receptors do not couple to identical downstream signaling proteins and pathways. For example, phosphorylation sites on EGFR and ERBB2 couple to the RAS/MAPK pathway via GRB2 and SOS [127,137,189,197]. Phosphorylated ERBB3 and ERBB4 each possess at least one PI3K binding site, whereas phosphorylated ERBB4 also possesses binding sites for YAP, STAT5a, STAT1, and PLC γ [112,114,127,140,144,199–201].

One consequence of this specificity is that receptor homodimers and heterodimers may exhibit distinct signaling properties and may stimulate distinct biological effects. For example, ERBB4 homodimers commonly function as tumor suppressors by stimulating apoptosis or growth arrest. In contrast, ERBB4-EGFR or ERBB4-ERBB2 heterodimers function as oncoproteins by stimulating cell proliferation and suppressing apoptosis [114,144,202–204]. The mechanism of this specificity is unclear, although context-specific sites of ERBB receptor tyrosine phosphorylation confer other forms of ERBB receptor signaling specificity [114,119,139,191–198,205,206].

An additional complexity of the ERBB/EGF signaling network is the non-canonical signaling exhibited by ERBB4. Following ligand binding to ERBB4, the transmembrane metalloprotease tumor necrosis factor alpha (TNF α) converting enzyme (TACE) cleaves the ERBB4 extracellular domain near the transmembrane domain. This releases the 120 kDa extracellular domain into the extracellular milieu, where it can act as a ligand sink [111,114,207–212]. Then, the gamma-secretase complex cleaves the ERBB4 cytoplasmic domain near the transmembrane domain. This releases the 80 kDa cytoplasmic region of ERBB4 (4ICD) from the plasma membrane [114,207–211,213–215].

The cytoplasmic region of ERBB4 contains a Bcl2 homology 3 (BH3) domain, which can bind pro- or anti-apoptotic proteins of the BAX/BAK or BCL-2 families. Homotypic 4ICD signaling triggers apoptosis by stimulating BAK oligomerization within the outer mitochondrial membrane (OMM). This may occur via 4ICD binding to BAK or through binding and sequestration of BCL-XL or other anti-apoptotic proteins [114,216]. BAK oligomerization triggers OMM permeability, resulting in increased cytochrome C efflux and caspase activation [111,114,124,146,215]. Signaling by ERBB4-EGFR or ERBB4-ERBB2 heterodimers suppresses 4ICD-induced apoptosis by an unknown mechanism.

The cytoplasmic region of ERBB4 also contains a nuclear localization signal [114,208,210,213,217] and two LXXLL motifs, which mediate interactions with nuclear (steroid) hormone receptors [114,218]. Homotypic 4ICD signaling stimulates estrogen receptor alpha signaling and increases the sensitivity of breast cancer cells to tamoxifen [111,114,125,141,219]. The 4ICD apparently regulates the function of other transcriptional regulatory proteins, including YAP1 [111,114,125,140,215,219], STAT5a [111,125,140,217], ETO2 [111,125,214,219], TAB2-NCOR [111,125,211,219], and AP-2 [125,219].

Crosstalk between GPCRs and ERBB receptors provides additional mechanisms by which ERBB receptor signaling can be regulated and specified. This crosstalk has been observed in numerous contexts and appears to occur via multiple mechanisms [120,121,220–224].

(a) Some GPCRs stimulate the activity of the Src non-receptor tyrosine kinase. Src directly phosphorylates EGFR tyrosine residues, thereby coupling EGFR to downstream signaling effectors [120,121,220–225]. (b) Some GPCRs complex with EGFR and stimulate EGFR tyrosine phosphorylation, presumably by stabilizing EGFR dimerization [220,221,226]. (c) A well-explored mechanism of GPCR-ERBB receptor crosstalk (Figure 3) appears to involve Src stimulation of the expression or activity of a matrix metalloproteinase (MMP) or an ADAM (a disintegrin and metalloproteinase). The metalloproteinase cleaves the transmembrane precursor form of an EGF family peptide hormone, releasing the mature hormone into the extracellular milieu. This enables ligand binding to ERBB receptors, and ligand-induced ERBB receptor dimerization and signaling [110,113,115–118,120,121,220–225]. (d) Stimulation of ERBB ligand maturation by GPCRs acting through MMP/ADAM activity may also be mediated by reactive oxygen species [117,118]. Direct evidence of CYSLTR2 and EGFR crosstalk has been observed in primary human bronchial fibroblasts, in which the CYSLTR2 agonist leukotriene C4 (LTC₄) potentiates the mitogenic effect of EGF [227].




Figure 3. GPCR-EGFR Crosstalk. Figure 3 Legend: This figure illustrates mechanisms by which a GPCR can stimulate ERBB receptor signaling via cleavage (maturation) of a precursor form of an EGF family growth factor. Created in BioRender. Riese, D. (2026) <https://BioRender.com/p5kjegtr> (accessed on 19 July 2026) [228].

4. Multiple Signaling Changes Are Observed in UM

4.1. CYSLTR2, $G_{\alpha q}$, and $G_{\alpha 11}$

CYSLTR2 encodes cysteinyl-leukotriene receptor 2, a G protein-coupled receptor that signals through heterotrimeric G proteins containing $G_{\alpha q}$ or $G_{\alpha 11}$ subunits [229–232]. The most common genetic alterations in UM involve mutations in the *GNAQ* or *GNA11* genes [5,10,17,103,233], resulting in constitutive canonical $G_{\alpha q}/G_{\alpha 11}$ signaling through loss of $G_{\alpha q}$ or $G_{\alpha 11}$ GTPase activity [12,103,233]. Likewise, mutations in CYSLTR2 that stimulate $G_{\alpha q}$ or $G_{\alpha 11}$ signaling appear to drive UM [5,10,12,29,103,231–234].

4.2. PLCβ4

Phospholipase C beta 4 (PLCβ4) cleaves the membrane lipid phosphatidylinositol 4,5 bisphosphate (PIP₂), producing inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG). $G_{\alpha q}$ and $G_{\alpha 11}$ directly stimulate PLCβ4 [223]. This suggests that PLCβ4 may mediate CYSLTR2/ $G_{\alpha q}/G_{\alpha 11}$ signaling in UM. Indeed, activating mutations in *PLCB4* are found in UM [2,5,10,233,235,236]. Activating mutations in *GNAQ*, *GNA11*, *CYSLTR2*, and *PLCB4* are mutually exclusive [3,12,29,36,37,52,232,234,236], suggesting that these genes encode components of a single signaling pathway that drives UM by activating RAS-MAPK and PKC signaling [10,237,238].

4.3. RAS-MAPK

The RAS-MAPK (mitogen-activated protein kinase) signaling pathway is a major regulator of cellular proliferation. This pathway is commonly activated in UM by

CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ /PLC β signaling [10,12,233,237,239,240]; one mechanism may involve the phosphorylation of Thr133 in the RAS guanine nucleotide exchange factor Ras-GRP3, leading to GTP loading onto all three RAS isoforms. PKC may be responsible for this phosphorylation; however, the cited work did not demonstrate that PKC directly phosphorylates RasGRP3 in UM [12,240]. Another mechanism may involve IP₃-stimulated Ca²⁺ release, which activates CaM kinase II. CaM kinase II phosphorylates and inhibits the activity of the RAS GTPase-activating protein (RAS-GAP), resulting in decreased GTP hydrolysis by RAS and increased RAS signaling activity [230]. *MAPKAPK5* encodes the MAPK-activated protein kinase 5, which lies downstream of RAS isoforms. *MAPKAPK5* is mutated in approximately 2% of UM cases. The *MAPKAPK5* mutations support the hypothesis that the RAS-MAPK pathway contributes to UM. Frameshift mutations are the most common *MAPKAPK5* mutations in UM, suggesting that *MAPKAPK5* may negatively regulate signaling by the RAS-MAPK pathway in UM [10,52]. However, it is not known whether *MAPKAPK5* mutations are mutually exclusive with mutations in *GNAQ*, *GNA11*, *CYSLTR2*, or *PLCB4*. Therefore, it is not apparent that *MAPKAPK5* encodes a component of a single pathway encoded by *GNAQ*, *GNA11*, *CYSLTR2*, and *PLCB4*. In fact, the MEK inhibitors trametinib and selumetinib were ineffective in UM patients [241–243], suggesting that CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ /PLC β signaling activates additional pathways. Similarly, a combination of $G_{\alpha q}$ and MEK inhibitors is more effective in human UM cell lines than either agent alone [243].

4.4. PKC

Protein kinase C (PKC) is a serine-threonine kinase, and DAG and Ca²⁺ activate many PKC isoforms. Thus, PKC signaling is elevated in UM, presumably due to elevated CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ /PLC β 4 signaling [29]. PKC inhibitors have exhibited only modest effects in UM [29,244,245], suggesting that additional signaling pathways are activated in these tumors. Indeed, the combination of a PKC inhibitor and a MEK inhibitor exhibited greater effects than either drug alone in a preclinical model system [29,246]. Moreover, these data suggest that the MEK pathway is stimulated independently of PKC.

4.5. PI3K/AKT/mTOR

Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that phosphorylates the membrane phospholipid phosphatidylinositol (4,5) biphosphate (PIP₂), yielding phosphatidylinositol (3,4,5) trisphosphate (PIP₃). PIP₃ recruits Protein Kinase B (PKB/AKT) to the membrane, enabling AKT phosphorylation (at Thr308 and Ser473) and signaling activity. PIP₃ also stimulates signaling by PDK1 (phosphoinositide-dependent kinase-1), which phosphorylates AKT at Thr308. Ser473 of AKT is phosphorylated by a multiprotein complex (mTORC2) that features mTOR (mammalian target of rapamycin). The canonical PI3K/AKT/mTOR signaling pathway ultimately regulates the biochemical activity of GSK-3 β (glycogen synthase kinase 3-beta), FOXOs (forkhead box O proteins), TSC1/2 (tuberous sclerosis complex 1/2 proteins), S6K (ribosomal S6 kinase), and other effectors [10,247].

Elevated signaling by the PI3K/AKT/mTOR pathway is a characteristic of UMs that exhibit elevated CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ signaling [10,29,248]. For example, the *GNAQ*-mutant Mel270 and 92-1 uveal melanoma cell lines exhibit elevated PI3K/AKT/mTOR signaling, as evidenced by phosphorylation of AKT and GSK3. Likewise, the PI3K inhibitor LY294002 inhibits the proliferation of the Mel270 and 92-1 cell lines. However, LY294002 does not inhibit ERK1/2 phosphorylation in these cell lines, suggesting that the PI3K/AKT/mTOR and MAPK signaling pathways independently drive UM proliferation. Indeed, combinations of PI3K and MEK inhibitors are more effective in inhibiting the proliferation of UM cell lines than either class of inhibitor alone [17,239,249]. However,

the combination of trametinib and the AKT inhibitor GSK2141795 (GSK795) did not significantly improve survival in patients with metastatic UM [17,241,242,250]. Additional signaling events may contribute to UM proliferation. The discrepancy may also be due to tumor heterogeneity and adaptive resistance mechanisms in vivo.

4.6. Hippo/YAP

The Yes-Associated Protein (YAP) is a component of transcription factor complexes that include the TAZ (Transcriptional co-Activator with PDZ-binding motif) protein and TEAD transcription factors. These complexes regulate cellular homeostasis in part by preventing abnormal cell proliferation. The Hippo pathway, also known as the Salvador/Warts/Hippo pathway, regulates YAP/TAZ/TEAD complexes. This pathway was initially discovered in *D. melanogaster* and named after one of its major components, the Hippo protein kinase. However, this pathway exhibits substantial evolutionary conservation through mammals. Additional components downstream of Hippo include the mammalian STE20-like protein kinases (MST1/2) and the large tumor suppressor kinases 1/2 (LATS1/2) [251,252].

The Hippo/YAP pathway can be regulated by a variety of intracellular and extracellular signals, including GPCR- and receptor tyrosine kinase-mediated signaling. Hippo signaling initiates the MST/LATS kinase cascade, resulting in the phosphorylation of YAP/TAZ. Phosphorylated YAP/TAZ is retained in the cytoplasm and is degraded. Conversely, low levels of Hippo signaling cause reduced YAP/TAZ phosphorylation. Unphosphorylated YAP/TAZ translocates to the nucleus, driving cell proliferation [251,252]. The overexpression of YAP/TAZ is associated with poor clinical outcomes in breast, colorectal, and liver cancers [252].

Activating mutations in *GNAQ* or *GNA11* are associated with the dephosphorylation of YAP and TAZ in UM cells. Verteporfin, a drug that disrupts YAP/TEAD interactions, inhibits the proliferation of *GNAQ*/*GNA11*-mutant UM cells [29,253]. Focal adhesion kinase (FAK) stimulates YAP dephosphorylation via canonical and non-canonical pathways. Likewise, genetic ablation or pharmacological inhibition of FAK reduces proliferation in a *GNAQ*-mutant UM cell line [29,254]. Moreover, due to compensatory signaling, simultaneous inhibition of the RAS-MAPK and FAK/Hippo/YAP pathways may yield more favorable clinical responses than inhibiting either pathway individually [29,255].

4.7. JAK/STAT

Signal Transducers and Activators of Transcription (STAT proteins) are a family of transcription factors that regulate gene expression. Like many transcription factors, they reside in the cytoplasm and nucleus. The translocation of STAT proteins into the nucleus is required for them to function as transcription factors. STAT dimerization and translocation to the nucleus are commonly induced by STAT phosphorylation by members of the Janus kinase (JAK) family of non-receptor tyrosine kinases. Cytokine receptors and receptor tyrosine kinases are typically upstream stimuli of the JAK-STAT signaling pathway. Some STAT proteins stimulate the transcription of genes encoding proteins that inhibit apoptosis or promote cell proliferation, including Bcl-xL, cyclin D1, and c-myc. Likewise, elevated activity of a JAK/STAT pathway drives numerous cancers [256–259], and increased signaling by STAT3 [5,10,17,26,38] and STAT5 [10] is observed in UM. Because GPCR signaling is not typically directly coupled to JAK/STAT signaling, GPCR-ERBB receptor crosstalk may be responsible for the elevated JAK-STAT signaling observed in UM.

5. Is GPCR-ERBB Receptor Crosstalk Driving UM?

Given the diversity of ERBB/EGF receptor signaling, including non-canonical ERBB4 signaling, we postulate that crosstalk between the CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ pathway and

the ERBB/EGF network could be responsible for many of the changes in downstream signaling events implicated in UM, including changes in signaling by pro- and anti-apoptotic proteins [260,261], steroid hormone receptors [262–264], YAP [29,253–255], and STATs [5,10,17,26,38]. Nonetheless, we postulate that the CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ pathway stimulates the RAS-MAPK pathway (and perhaps the PI3K/AKT/mTOR pathway, given their crosstalk) independently of ERBB receptors. Therefore, these observations suggest that ERBB/EGF network signaling may cooperate with the RAS-MAPK pathway (and perhaps the PI3K/AKT/mTOR pathway) to drive UM cell proliferation, and that targeting the ERBB/EGF signaling network in combination with the RAS-MAPK or PI3K/AKT/mTOR pathway is likely to yield greater therapeutic effects than targeting either pathway alone.

This mechanistic model for UM resembles that for human CMs with wild-type *BRAF* alleles (“*BRAF*-WT melanomas”). In such tumors, *ERBB4* transcription or an *ERBB4* gain-of-function mutant allele appears to segregate with a gain-of-function *RAS* allele or a loss-of-function *NF1* allele. Thus, *ERBB4* signaling appears to cooperate with the RAS-MAPK pathway to drive *BRAF*-WT melanomas [265,266]. Moreover, ectopic expression of an *ERBB4* dominant-negative mutant allele inhibits the clonogenic proliferation of four *BRAF*-WT melanoma cell lines (IPC-298, MEL-JUSO, MeWo, and SK-MEL-2) [265]. Our lab is working to identify actionable targets within the *ERBB4* signaling pathway in these *ERBB4*-dependent *BRAF*-WT melanoma cell lines. For example, our preliminary observation that *ERBB2* is both sufficient and necessary for the proliferation of three *ERBB4*-dependent, *BRAF*-WT melanoma cell lines (IPC-298, MEL-JUSO, and MeWo) suggests that targeting *ERBB4*-*ERBB2* heterodimer signaling may be effective in some *BRAF*-WT melanomas [267].

Four *ERBB4*-dependent *BRAF*-WT melanoma cell lines (IPC-298, MEL-JUSO, MeWo, and SK-MEL-2) harbor apparent driver mutations in *GNA11* or *PLCB4* [268]. These findings suggest that these cell lines display elevated expression of mature (soluble) ERBB receptor ligands, leading to increased signaling by *ERBB4* heterodimers. Because *GNA11* or *PLCB4* driver mutations are found in many UMs, UMs may likewise depend on the ERBB/EGF signaling network. Therefore, insights into targeting *ERBB4*-dependent *BRAF*-WT CMs may apply to *GNAQ*/*GNA11* mutant UMs. Appropriate cell culture models of *GNAQ*/*GNA11* mutant UM exist for such experiments [269–271].

Limited evidence supports the hypothesis that the ERBB/EGF signaling network cooperates with the CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ signaling pathway to drive UM. A validated tumor driver mutation in *EGFR* was observed in two of 83 primary UM samples that possess a *GNAQ* or *GNA11* driver mutation [272]. Likewise, *EGFR* expression has been documented in multiple UM cell lines, and the extent of liver metastasis in xenografted immunocompromised mice appears to correlate with *EGFR* expression levels. Metastasis to the liver was inhibited by the anti-*EGFR* mouse monoclonal antibody 225 (the antecedent of cetuximab) and was accompanied by enhanced survival in xenografted mice [273].

Eight years of follow-up data from 18 UM patients indicate *EGFR* expression in primary tumor samples correlates with a marked decrease in survival [274]. This finding is somewhat contradicted by the results of a study of 30 primary UM samples, in which *EGFR* expression was restricted to cells with a macrophage-like morphology, and limited follow-up data did not reveal a correlation between *EGFR* expression and survival [275]. Likewise, analyses of *EGFR* expression in 60 primary UM samples did not reveal a correlation between *EGFR* and the incidence of liver metastasis or survival [276].

Elevated *EGFR* transcription was observed in eight of 48 primary UM samples and two of 14 UM cell lines. However, gene expression profiling of the 48 primary UM samples indicates that a gene expression profile indicative of *EGFR* signaling does not correlate with elevated *EGFR* transcription. This work postulated that increased endogenous ligand

maturation (resulting from crosstalk between the CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ signaling pathway and the ERBB/EGF signaling network) and elevated ligand-dependent EGFR signaling would account for this apparent dichotomy and called for UM clinical trials of anti-EGFR agents [178].

Initial attempts to use small-molecule inhibitors to test the hypothesis that the ERBB/EGF signaling network cooperates with the RAS/MAPK pathway to drive UM have yielded intriguing results. The first-generation EGFR tyrosine kinase inhibitor gefitinib failed to yield a significant benefit in a small number ($n = 6$) of unselected patients with metastatic choroidal UM [12,277]. Of course, this negative result may be due to the small sample size and a lack of biomarker-based patient selection. Moreover, as we have postulated elsewhere, the combination of an ERBB/EGF network inhibitor with a RAS-MAPK pathway inhibitor (and possibly a PI3K/AKT/mTOR pathway inhibitor) may be necessary to elicit a clinically relevant response. Indeed, erlotinib (another first-generation EGFR tyrosine kinase inhibitor), everolimus (mTOR inhibitor), selumetinib (MEK inhibitor), and trametinib (MEK inhibitor) each modestly inhibit the proliferation of three *GNAQ/GNA11* mutant UM cell lines, again suggesting that combinations may be necessary to elicit robust responses [278]. GZ17-6.02, a synthetic conjugate of curcumin, harmine, and isovanillin, exhibited tolerable toxicity and slightly reduced the tumor mass in a metastatic uveal melanoma patient in a phase I clinical trial (NCT03775525) [279,280]. GZ17-6.02 apparently kills tumor cells by targeting signaling pathways, including ataxia telangiectasia (ATM), mTORC1, BAX, BAK, and ERBB receptors. Moreover, GZ17-6.02 sensitizes UM cell lines to the ERBB2 tyrosine kinase inhibitor neratinib [280].

6. Conclusions

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, annually accounting for 4–7 cases per million individuals worldwide. The typical treatment for primary UM includes radiotherapy, photocoagulation, thermotherapy, and surgery. These primary treatment options are, in some respects, quite effective, as the median time to progression to metastatic UM is measured in years. However, metastatic UM is relatively lethal, as the mortality rate at 10–15 years after diagnosis of the primary tumor is approximately 40–50%. This mortality is in part due to the absence of an effective standard treatment for metastatic UM.

Thus, there has been much interest in the molecular characterization of UM. As noted elsewhere, mutations in the CYSLTR2/ $G_{\alpha q}$ / $G_{\alpha 11}$ /PLC β 4 GPCR signaling pathway appear to drive a significant proportion of UM. However, $G_{\alpha q}$ and $G_{\alpha 11}$ are not yet suitable targets for treating metastatic UM. Thus, the identification of candidate targets downstream of $G_{\alpha q}$ / $G_{\alpha 11}$ has been a priority and has yielded PKC, the RAS/MAPK pathway, the PI3K/AKT/mTOR pathway, the Hippo/YAP pathway, and the JAK/STAT pathway. However, it is impractical to implement combination therapy regimens that target this multitude of pathways, particularly when attempting to prevent progression of occult UM micrometastases. Thus, identifying a signaling nexus proximal to $G_{\alpha q}$ / $G_{\alpha 11}$ that regulates the multitude of $G_{\alpha q}$ / $G_{\alpha 11}$ effector pathways is critical.

We propose that the ERBB/EGF signaling network is such a nexus and that targeting it may be effective against UM by simultaneously blocking these pathways. This hypothesis is supported by evidence that the $G_{\alpha q}$ / $G_{\alpha 11}$ signaling pathway can stimulate ERBB receptor signaling. Several mechanisms have been proposed for this crosstalk. However, one of the most common mechanisms involves Src-dependent stimulation of MMPs/ADAMs, which cleave the precursor, transmembrane forms of EGF family peptide hormones. The release of soluble, mature forms of EGF family hormones enables them to bind to ERBB receptors and stimulate receptor signaling. Receptor signaling may feature both ERBB receptor

homodimerization and heterodimerization. Signaling by receptor heterodimers may be particularly important, as they enable more complex downstream signaling than receptor homodimers. Experimental data support the proposed $G_{\alpha q}/G_{\alpha 11}$ -ERBB crosstalk in UM. In human bronchial fibroblasts, the CYSLTR2 agonist LTC4 potentiates the mitogenic effect of EGF. Four *ERBB4*-dependent BRAF-WT melanoma cell lines possess apparent driver mutations in *GNA11* or *PLCB4*, suggesting that the elevated ERBB4 signaling in these BRAF-WT melanoma cell lines is due to increased maturation of soluble EGF family hormones. Human UM cell lines harboring driver mutations in *GNA11* or *GNAQ* could be used to test the hypothesis that they are ERBB-dependent.

Further investigation is needed to clarify whether ERBB/EGF network activation occurs in UM and serves as a mechanistic link between canonical CYSLTR2/ $G_{\alpha q}/G_{\alpha 11}$ /PLC β signaling and broader oncogenic pathways. Defining these interactions may identify more effective combinatorial therapeutic strategies for metastatic UM. Candidates for such studies are illustrated in Figure 1 and include the non-receptor tyrosine kinase Src; MMPs and ADAMs that might be responsible for cleavage of precursor forms of EGF family growth factors; the individual ERBB receptors, and the EGF family growth factors themselves.

Of course, acquired resistance to agents targeting the ERBB/EGF network has impacted the utility of this treatment paradigm. In some tumors treated with ERBB tyrosine kinase inhibitors (TKIs), on-target mutations abrogate inhibitor efficacy by reducing drug binding. In many instances, this resistance can be overcome by later-generation TKIs, particularly covalent, irreversible TKIs. In other tumors treated with agents that target ERBB receptors, acquired resistance can arise through activation of bypass pathways. In many instances, this resistance is caused by increased signaling by other receptor tyrosine kinases, including signaling stimulated by growth factors present in the complex milieu of the tumor microenvironment. Obviously, this creates additional opportunities for therapeutic intervention. Thus, acquired resistance to agents targeting the ERBB/EGF network remains a clinical challenge but should not be the sole reason for not investigating inhibitors of this network as a treatment paradigm.

Author Contributions: Conceptualization: D.J.R.II; Writing—Original Draft Preparation: N.R. and D.J.R.II; Writing—Review and Editing: N.R. and D.J.R.II; Supervision—D.J.R.II; Funding Acquisition—D.J.R.II. All authors have read and agreed to the published version of the manuscript.

Funding: This work has been supported by the United States National Institutes of Health (1R15CA280767-01A1).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: As a review article, this work does not contain primary data. Hence, no primary data are available to share.

Conflicts of Interest: D.J.R.II has been a consultant for Bristol-Myers Squibb, Eli Lilly and Company, and ImClone Systems. D.J.R.II is no longer affiliated with these organizations. Thus, this work does not represent a financial conflict of interest.

References

1. Singh, A.D.; Turell, M.E.; Topham, A.K. Uveal melanoma: Trends in incidence, treatment, and survival. *Ophthalmology* **2011**, *118*, 1881–1885. [[CrossRef](#)] [[PubMed](#)]
2. Kaliki, S.; Shields, C.L. Uveal melanoma: Relatively rare but deadly cancer. *Eye* **2017**, *31*, 241–257. [[CrossRef](#)] [[PubMed](#)]
3. Damato, B.E.; Dukes, J.; Goodall, H.; Carvajal, R.D. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. *Cancers* **2019**, *11*, 971. [[CrossRef](#)] [[PubMed](#)]

4. Piperno-Neumann, S.; Piulats, J.M.; Goebeler, M.; Galloway, I.; Lugowska, I.; Becker, J.C.; Vihinen, P.; Van Calster, J.; Hadjistilianou, T.; Proenca, R.; et al. Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. *Cancers* **2019**, *11*, 817. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Sorrentino, F.S.; Culiersi, C.; Florido, A.; De Nadai, K.; Adamo, G.G.; Nasini, F.; Vivarelli, C.; Mura, M.; Parmeggiani, F. Genetic Features of Uveal Melanoma. *Genes* **2024**, *15*, 1356. [\[CrossRef\]](#) [\[PubMed\]](#)
6. Synoradzki, K.J.; Paduszynska, N.; Solnik, M.; Toro, M.D.; Bilmin, K.; Bylina, E.; Rutkowski, P.; Yousef, Y.A.; Bucolo, C.; Zweifel, S.A.; et al. From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma. *Curr. Oncol.* **2024**, *31*, 778–800. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Harbour, J.W. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. *Methods Mol. Biol.* **2014**, *1102*, 427–440. [\[CrossRef\]](#) [\[PubMed\]](#)
8. Onken, M.D.; Worley, L.A.; Ehlers, J.P.; Harbour, J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. *Cancer Res.* **2004**, *64*, 7205–7209. [\[CrossRef\]](#) [\[PubMed\]](#)
9. Egan, K.M.; Seddon, J.M.; Glynn, R.J.; Gragoudas, E.S.; Albert, D.M. Epidemiologic aspects of uveal melanoma. *Surv. Ophthalmol.* **1988**, *32*, 239–251. [\[CrossRef\]](#) [\[PubMed\]](#)
10. Fuentes-Rodriguez, A.; Mitchell, A.; Guerin, S.L.; Landreville, S. Recent Advances in Molecular and Genetic Research on Uveal Melanoma. *Cells* **2024**, *13*, 1023. [\[CrossRef\]](#) [\[PubMed\]](#)
11. Singh, S.R.K.; Malapati, S.J.; Kumar, R.; Willner, C.; Wang, D. NCDB Analysis of Melanoma 2004–2015: Epidemiology and Outcomes by Subtype, Sociodemographic Factors Impacting Clinical Presentation, and Real-World Survival Benefit of Immunotherapy Approval. *Cancers* **2021**, *13*, 1455. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Carvajal, R.D.; Sacco, J.J.; Jager, M.J.; Eschelman, D.J.; Olofsson Bagge, R.; Harbour, J.W.; Chieng, N.D.; Patel, S.P.; Joshua, A.M.; Piperno-Neumann, S. Advances in the clinical management of uveal melanoma. *Nat. Rev. Clin. Oncol.* **2023**, *20*, 99–115. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Damato, B.E.; Coupland, S.E. Differences in uveal melanomas between men and women from the British Isles. *Eye* **2012**, *26*, 292–299. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Damato, B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. *Eye* **2012**, *26*, 1157–1172. [\[CrossRef\]](#) [\[PubMed\]](#)
15. Krantz, B.A.; Dave, N.; Komatsubara, K.M.; Marr, B.P.; Carvajal, R.D. Uveal melanoma: Epidemiology, etiology, and treatment of primary disease. *Clin. Ophthalmol.* **2017**, *11*, 279–289. [\[CrossRef\]](#) [\[PubMed\]](#)
16. Gelmi, M.C.; Jager, M.J. Uveal melanoma: Current evidence on prognosis, treatment and potential developments. *Asia Pac. J. Ophthalmol.* **2024**, *13*, 100060. [\[CrossRef\]](#) [\[PubMed\]](#)
17. Kulbay, M.; Marcotte, E.; Remtulla, R.; Lau, T.H.A.; Paez-Escamilla, M.; Wu, K.Y.; Burnier, M.N., Jr. Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives. *Biomedicines* **2024**, *12*, 1758. [\[CrossRef\]](#) [\[PubMed\]](#)
18. Damato, B. Ocular treatment of choroidal melanoma in relation to the prevention of metastatic death—A personal view. *Prog. Retin. Eye Res.* **2018**, *66*, 187–199. [\[CrossRef\]](#) [\[PubMed\]](#)
19. Jensen, O.A. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943–1952. *Acta Ophthalmol.* **1982**, *60*, 161–182. [\[CrossRef\]](#) [\[PubMed\]](#)
20. Kujala, E.; Makitie, T.; Kivela, T. Very long-term prognosis of patients with malignant uveal melanoma. *Investig. Ophthalmol. Vis. Sci.* **2003**, *44*, 4651–4659. [\[CrossRef\]](#) [\[PubMed\]](#)
21. Carvajal, R.D.; Schwartz, G.K.; Tezel, T.; Marr, B.; Francis, J.H.; Nathan, P.D. Metastatic disease from uveal melanoma: Treatment options and future prospects. *Br. J. Ophthalmol.* **2017**, *101*, 38–44. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Aronow, M.E.; Topham, A.K.; Singh, A.D. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973–2013). *Ocul. Oncol. Pathol.* **2018**, *4*, 145–151. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Khoja, L.; Atenafu, E.G.; Suci, S.; Leyvraz, S.; Sato, T.; Marshall, E.; Keilholz, U.; Zimmer, L.; Patel, S.P.; Piperno-Neumann, S.; et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: An international rare cancers initiative (IRCI) ocular melanoma study. *Ann. Oncol.* **2019**, *30*, 1370–1380. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Rantala, E.S.; Hernberg, M.; Kivela, T.T. Overall survival after treatment for metastatic uveal melanoma: A systematic review and meta-analysis. *Melanoma Res.* **2019**, *29*, 561–568. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Jager, M.J.; Shields, C.L.; Cebulla, C.M.; Abdel-Rahman, M.H.; Grossniklaus, H.E.; Stern, M.H.; Carvajal, R.D.; Belfort, R.N.; Jia, R.; Shields, J.A.; et al. Uveal melanoma. *Nat. Rev. Dis. Prim.* **2020**, *6*, 24. [\[CrossRef\]](#) [\[PubMed\]](#)
26. Bustamante, P.; Piquet, L.; Landreville, S.; Burnier, J.V. Uveal melanoma pathobiology: Metastasis to the liver. *Semin. Cancer Biol.* **2021**, *71*, 65–85. [\[CrossRef\]](#) [\[PubMed\]](#)
27. Roelofsen, C.D.M.; Wierenga, A.P.A.; van Duinen, S.; Verdijk, R.M.; Bleeker, J.; Marinkovic, M.; Luyten, G.P.M.; Jager, M.J. Five Decades of Enucleations for Uveal Melanoma in One Center: More Tumors with High Risk Factors, No Improvement in Survival over Time. *Ocul. Oncol. Pathol.* **2021**, *7*, 133–141. [\[CrossRef\]](#) [\[PubMed\]](#)

28. Stalhammar, G. Comprehensive causes of death in uveal melanoma: Mortality in 1530 consecutively diagnosed patients followed until death. *JNCI Cancer Spectr.* **2023**, *7*, pkad097. [CrossRef] [PubMed]
29. Liu, X.L.; Run-Hua, Z.; Pan, J.X.; Li, Z.J.; Yu, L.; Li, Y.L. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations. *Pigment. Cell Melanoma Res.* **2024**, *37*, 411–425. [CrossRef] [PubMed]
30. van Gils, W.; Lodder, E.M.; Mensink, H.W.; Kilic, E.; Naus, N.C.; Bruggenwirth, H.T.; van Ijcken, W.; Paridaens, D.; Luyten, G.P.; de Klein, A. Gene expression profiling in uveal melanoma: Two regions on 3p related to prognosis. *Investig. Ophthalmol. Vis. Sci.* **2008**, *49*, 4254–4262. [CrossRef] [PubMed]
31. NCCN Guidelines: Melanoma: Uveal, Version 1. 2025. Available online: https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf (accessed on 23 July 2025).
32. Houtzagers, L.E.; Wierenga, A.P.A.; Ruys, A.A.M.; Luyten, G.P.M.; Jager, M.J. Iris Colour and the Risk of Developing Uveal Melanoma. *Int. J. Mol. Sci.* **2020**, *21*, 7172. [CrossRef] [PubMed]
33. Wu, M.; Yavuziyigitoglu, S.; Brosens, E.; Ramdas, W.D.; Kilic, E.; Rotterdam Ocular Melanoma Study Group (ROMS). Worldwide Incidence of Ocular Melanoma and Correlation With Pigmentation-Related Risk Factors. *Investig. Ophthalmol. Vis. Sci.* **2023**, *64*, 45. [CrossRef] [PubMed]
34. Royer-Bertrand, B.; Torsello, M.; Rimoldi, D.; El Zaoui, I.; Cisarova, K.; Pescini-Gobert, R.; Raynaud, F.; Zografos, L.; Schalenbourg, A.; Speiser, D.; et al. Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing. *Am. J. Hum. Genet.* **2016**, *99*, 1190–1198. [CrossRef] [PubMed]
35. Chalmers, Z.R.; Connelly, C.F.; Fabrizio, D.; Gay, L.; Ali, S.M.; Ennis, R.; Schrock, A.; Campbell, B.; Shlien, A.; Chmielecki, J.; et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med.* **2017**, *9*, 34. [CrossRef] [PubMed]
36. Van Raamsdonk, C.D.; Bezrookove, V.; Green, G.; Bauer, J.; Gaugler, L.; O'Brien, J.M.; Simpson, E.M.; Barsh, G.S.; Bastian, B.C. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature* **2009**, *457*, 599–602. [CrossRef] [PubMed]
37. Van Raamsdonk, C.D.; Griewank, K.G.; Crosby, M.B.; Garrido, M.C.; Vemula, S.; Wiesner, T.; Obenaus, A.C.; Wackernagel, W.; Green, G.; Bouvier, N.; et al. Mutations in GNA11 in uveal melanoma. *N. Engl. J. Med.* **2010**, *363*, 2191–2199. [CrossRef] [PubMed]
38. van der Kooij, M.K.; Speetjens, F.M.; van der Burg, S.H.; Kapiteijn, E. Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. *Cancers* **2019**, *11*, 845. [CrossRef] [PubMed]
39. Wessely, A.; Koch, E.A.T.; Vera, J.; Berking, C.; Heppt, M.V. Identifying biomarkers and novel therapeutic targets in uveal melanoma. *J. Dtsch. Dermatol. Ges.* **2024**, *22*, 29–32. [CrossRef] [PubMed]
40. Reichstein, D.A.; Brock, A.L. Radiation therapy for uveal melanoma: A review of treatment methods available in 2021. *Curr. Opin. Ophthalmol.* **2021**, *32*, 183–190. [CrossRef] [PubMed]
41. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. *Arch. Ophthalmol.* **2001**, *119*, 670–676. [CrossRef] [PubMed]
42. Baum, S.H.; Westekemper, H.; Bechrakis, N.E.; Mohr, C. Conjunctival and uveal melanoma: Survival and risk factors following orbital exenteration. *Eur. J. Ophthalmol.* **2022**, *32*, 612–619. [CrossRef] [PubMed]
43. Heng, J.S.; Perzia, B.M.; Sinard, J.H.; Pointdujour-Lim, R. Local recurrence of uveal melanoma and concomitant brain metastases associated with an activating telomerase promoter mutation seven years after secondary enucleation. *Am. J. Ophthalmol. Case Rep.* **2022**, *27*, 101607. [CrossRef] [PubMed]
44. Negretti, G.S.; Gurudas, S.; Gallo, B.; Damato, B.; Arora, A.K.; Sivaprasad, S.; Sagoo, M.S. Survival analysis following enucleation for uveal melanoma. *Eye* **2022**, *36*, 1669–1674. [CrossRef] [PubMed]
45. Lorenzo, D.; Piulats, J.M.; Ochoa, M.; Arias, L.; Gutierrez, C.; Catala, J.; Cobos, E.; Garcia-Bru, P.; Dias, B.; Padron-Perez, N.; et al. Clinical predictors of survival in metastatic uveal melanoma. *Jpn. J. Ophthalmol.* **2019**, *63*, 197–209. [CrossRef] [PubMed]
46. Onken, M.D.; Worley, L.A.; Tuscan, M.D.; Harbour, J.W. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. *J. Mol. Diagn.* **2010**, *12*, 461–468. [CrossRef] [PubMed]
47. Gamel, J.W.; McLean, I.W.; McCurdy, J.B. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. *Cancer* **1993**, *71*, 2299–2305. [CrossRef]
48. Stalhammar, G.; Herrspiegel, C. Long-term relative survival in uveal melanoma: A systematic review and meta-analysis. *Commun. Med.* **2022**, *2*, 18. [CrossRef] [PubMed]
49. Bidard, F.C.; Madic, J.; Mariani, P.; Piperno-Neumann, S.; Rampanou, A.; Servois, V.; Cassoux, N.; Desjardins, L.; Milder, M.; Vaucher, I.; et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. *Int. J. Cancer* **2014**, *134*, 1207–1213. [CrossRef] [PubMed]
50. Cabel, L.; Riva, F.; Servois, V.; Livartowski, A.; Daniel, C.; Rampanou, A.; Lantz, O.; Romano, E.; Milder, M.; Buecher, B.; et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: A proof-of-concept study. *Ann. Oncol.* **2017**, *28*, 1996–2001. [CrossRef] [PubMed]

51. Park, J.J.; Diefenbach, R.J.; Byrne, N.; Long, G.V.; Scolyer, R.A.; Gray, E.S.; Carlino, M.S.; Rizos, H. Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. *Cancers* **2021**, *13*, 1740. [[CrossRef](#)] [[PubMed](#)]
52. Robertson, A.G.; Shih, J.; Yau, C.; Gibb, E.A.; Oba, J.; Mungall, K.L.; Hess, J.M.; Uzunangelov, V.; Walter, V.; Danilova, L.; et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. *Cancer Cell* **2017**, *32*, 204–220.e215. [[CrossRef](#)] [[PubMed](#)]
53. Harbour, J.W.; Onken, M.D.; Roberson, E.D.; Duan, S.; Cao, L.; Worley, L.A.; Council, M.L.; Matatall, K.A.; Helms, C.; Bowcock, A.M. Frequent mutation of BAP1 in metastasizing uveal melanomas. *Science* **2010**, *330*, 1410–1413. [[CrossRef](#)] [[PubMed](#)]
54. Darvin, P.; Toor, S.M.; Sasidharan Nair, V.; Elkord, E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. *Exp. Mol. Med.* **2018**, *50*, 1–11. [[CrossRef](#)] [[PubMed](#)]
55. Yun, S.; Vincelette, N.D.; Green, M.R.; Wahner Hendrickson, A.E.; Abraham, I. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: A systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. *Cancer Med.* **2016**, *5*, 1481–1491. [[CrossRef](#)] [[PubMed](#)]
56. Champion, P.J.; Bluestein, J.R.; Quinn, A.E.; Bell, S.D.; Kiley, J.H.; Wakefield, M.R.; Fang, Y. A Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma. *Biomedicines* **2025**, *13*, 1388. [[CrossRef](#)] [[PubMed](#)]
57. Timis, T.; Buruiana, S.; Dima, D.; Nistor, M.; Muresan, X.M.; Cenariu, D.; Tigu, A.B.; Tomuleasa, C. Advances in Cell and Immune Therapies for Melanoma. *Biomedicines* **2025**, *13*, 98. [[CrossRef](#)] [[PubMed](#)]
58. Wang, X.; Ma, S.; Zhu, S.; Zhu, L.; Guo, W. Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma. *Biomedicines* **2025**, *13*, 225. [[CrossRef](#)] [[PubMed](#)]
59. Saleem, M.; Watson, A.E.; Anwaar, A.; Jasser, A.O.; Yusuf, N. Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment. *Biomolecules* **2025**, *15*, 589. [[CrossRef](#)] [[PubMed](#)]
60. Triggiano, G.; Pezzicoli, G.; Tucci, M. Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events. *Biomolecules* **2025**, *15*, 651. [[CrossRef](#)] [[PubMed](#)]
61. Wang, T.; Ma, W.; Zou, Z.; Zhong, J.; Lin, X.; Liu, W.; Sun, W.; Hu, T.; Xu, Y.; Chen, Y. PD-1 blockade treatment in melanoma: Mechanism of response and tumor-intrinsic resistance. *Cancer Sci.* **2025**, *116*, 329–337. [[CrossRef](#)] [[PubMed](#)]
62. Lens, M.; Schachter, J. Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data. *Cancers* **2025**, *17*, 1835. [[CrossRef](#)] [[PubMed](#)]
63. Muto, Y.; Fujimura, T.; Asano, Y. Recent Advances in Immunotherapy for Melanoma: Perspectives on the Development of Novel Treatments: A Mini Review. *Cancers* **2025**, *17*, 2265. [[CrossRef](#)] [[PubMed](#)]
64. Latoni, D.I.; Kim, S.H.; Tsao, H. Systemic Therapies for Metastatic Melanoma. *Dermatol. Clin.* **2025**, *43*, 483–494. [[CrossRef](#)] [[PubMed](#)]
65. Pham, J.P.; Staeger, R.; Joshua, A.M.; Liu, J.; da Silva, I.P.; Dummer, R.; Goldinger, S.M. An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma. *Eur. J. Cancer* **2025**, *214*, 115121. [[CrossRef](#)] [[PubMed](#)]
66. Maul, L.V.; Ramelyte, E.; Dummer, R.; Mangana, J. Management of metastatic melanoma with combinations including PD-1 inhibitors. *Expert Opin. Biol. Ther.* **2025**, *25*, 487–498. [[CrossRef](#)] [[PubMed](#)]
67. McCombe, A.; van Akkooi, A.C.J. An evaluation of nivolumab and ipilimumab for the treatment of resectable stage III melanoma. *Expert Rev. Anticancer. Ther.* **2025**, *25*, 999–1005. [[CrossRef](#)] [[PubMed](#)]
68. Patel, S.P.; Sheth, R.A.; Davis, C.; Medina, T. Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary. *J. Clin. Oncol.* **2025**, *43*, 907–911. [[CrossRef](#)] [[PubMed](#)]
69. Tasdogan, A.; Sullivan, R.J.; Katalinic, A.; Lebbe, C.; Whitaker, D.; Puig, S.; van de Poll-Franse, L.V.; Massi, D.; Schadendorf, D. Cutaneous melanoma. *Nat. Rev. Dis. Prim.* **2025**, *11*, 23. [[CrossRef](#)] [[PubMed](#)]
70. Pathak, S.; Puckett, Y. Cutaneous Malignant Melanoma: Guideline-Based Management and Interprofessional Collaboration. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2025.
71. Shah, A.; Decoste, R.; Vanderbeck, K.; Sharma, A.; Roy, S.F.; Naert, K.; Osmond, A. Molecular-Guided Therapy for Melanoma in Canada: Overview of Current Practices and Recommendations. *J. Cutan. Med. Surg.* **2025**, *29*, 290–297. [[CrossRef](#)] [[PubMed](#)]
72. Swetter, S.M.; Johnson, D.; Albertini, M.R.; Barker, C.A.; Bateni, S.; Baumgartner, J.; Bhatia, S.; Bichakjian, C.; Boland, G.; Chandra, S.; et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024. *J. Natl. Compr. Cancer Netw.* **2024**, *22*, 290–298. [[CrossRef](#)] [[PubMed](#)]
73. Wessely, A.; Steeb, T.; Erdmann, M.; Heinzerling, L.; Vera, J.; Schlaak, M.; Berking, C.; Heppt, M.V. The Role of Immune Checkpoint Blockade in Uveal Melanoma. *Int. J. Mol. Sci.* **2020**, *21*, 879. [[CrossRef](#)] [[PubMed](#)]
74. Wierenga, A.P.A.; Cao, J.; Luyten, G.P.M.; Jager, M.J. Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma. *Int. Ophthalmol. Clin.* **2019**, *59*, 53–63. [[CrossRef](#)] [[PubMed](#)]
75. van der Kooij, M.K.; Joosse, A.; Speetjens, F.M.; Hospers, G.A.; Bisschop, C.; de Groot, J.W.; Koornstra, R.; Blank, C.U.; Kapiteijn, E. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. *Acta Oncol.* **2017**, *56*, 101–103. [[CrossRef](#)] [[PubMed](#)]

76. Johansson, P.A.; Stark, A.; Palmer, J.M.; Bigby, K.; Brooks, K.; Rolfe, O.; Pritchard, A.L.; Whitehead, K.; Warrier, S.; Glasson, W.; et al. Prolonged stable disease in a uveal melanoma patient with germline *MBD4* nonsense mutation treated with pembrolizumab and ipilimumab. *Immunogenetics* **2019**, *71*, 433–436. [\[CrossRef\]](#) [\[PubMed\]](#)
77. Rodrigues, M.; Mobuchon, L.; Houy, A.; Fievet, A.; Gardrat, S.; Barnhill, R.L.; Popova, T.; Servois, V.; Rampanou, A.; Mouton, A.; et al. Outlier response to anti-PD1 in uveal melanoma reveals germline *MBD4* mutations in hypermutated tumors. *Nat. Commun.* **2018**, *9*, 1866. [\[CrossRef\]](#) [\[PubMed\]](#)
78. Kastelan, S.; Antunica, A.G.; Oreskovic, L.B.; Pelcic, G.; Kasun, E.; Hat, K. Immunotherapy for Uveal Melanoma—Current Knowledge and Perspectives. *Curr. Med. Chem.* **2020**, *27*, 1350–1366. [\[CrossRef\]](#) [\[PubMed\]](#)
79. Johansson, P.A.; Brooks, K.; Newell, F.; Palmer, J.M.; Wilmott, J.S.; Pritchard, A.L.; Broit, N.; Wood, S.; Carlino, M.S.; Leonard, C.; et al. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. *Nat. Commun.* **2020**, *11*, 2408. [\[CrossRef\]](#) [\[PubMed\]](#)
80. Yarchoan, M.; Hopkins, A.; Jaffee, E.M. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. *N. Engl. J. Med.* **2017**, *377*, 2500–2501. [\[CrossRef\]](#) [\[PubMed\]](#)
81. Johnson, D.B.; Bao, R.; Ancell, K.K.; Daniels, A.B.; Wallace, D.; Sosman, J.A.; Luke, J.J. Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis. *J. Natl. Compr. Cancer Netw.* **2019**, *17*, 114–117. [\[CrossRef\]](#) [\[PubMed\]](#)
82. Algazi, A.P.; Tsai, K.K.; Shoushtari, A.N.; Munhoz, R.R.; Eroglu, Z.; Piulats, J.M.; Ott, P.A.; Johnson, D.B.; Hwang, J.; Daud, A.I.; et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. *Cancer* **2016**, *122*, 3344–3353. [\[CrossRef\]](#) [\[PubMed\]](#)
83. Helgadottir, H.; Hoim, V. The genetics of uveal melanoma: Current insights. *Appl. Clin. Genet.* **2016**, *9*, 147–155. [\[CrossRef\]](#) [\[PubMed\]](#)
84. Chandran, S.S.; Somerville, R.P.T.; Yang, J.C.; Sherry, R.M.; Klebanoff, C.A.; Goff, S.L.; Wunderlich, J.R.; Danforth, D.N.; Zlott, D.; Paria, B.C.; et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: A single-centre, two-stage, single-arm, phase 2 study. *Lancet Oncol.* **2017**, *18*, 792–802. [\[CrossRef\]](#) [\[PubMed\]](#)
85. Retel, V.P.; Steuten, L.M.G.; Geukes Foppen, M.H.; Mewes, J.C.; Lindenberg, M.A.; Haanen, J.; van Harten, W.H. Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: A model-based economic evaluation. *BMC Cancer* **2018**, *18*, 895. [\[CrossRef\]](#) [\[PubMed\]](#)
86. Rosenberg, S.A.; Yang, J.C.; Sherry, R.M.; Kammula, U.S.; Hughes, M.S.; Phan, G.Q.; Citrin, D.E.; Restifo, N.P.; Robbins, P.F.; Wunderlich, J.R.; et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin. Cancer Res.* **2011**, *17*, 4550–4557. [\[CrossRef\]](#) [\[PubMed\]](#)
87. Andersen, R.; Donia, M.; Ellebaek, E.; Borch, T.H.; Kongsted, P.; Iversen, T.Z.; Holmich, L.R.; Hendel, H.W.; Met, O.; Andersen, M.H.; et al. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. *Clin. Cancer Res.* **2016**, *22*, 3734–3745. [\[CrossRef\]](#) [\[PubMed\]](#)
88. Martinez-Perez, D.; Vinal, D.; Solares, I.; Espinosa, E.; Feliu, J. Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. *Cancers* **2021**, *13*, 5968. [\[CrossRef\]](#) [\[PubMed\]](#)
89. Wagner, S.N.; Wagner, C.; Schultewolter, T.; Goos, M. Analysis of Pmel17/gp100 expression in primary human tissue specimens: Implications for melanoma immuno- and gene-therapy. *Cancer Immunol. Immunother.* **1997**, *44*, 239–247. [\[CrossRef\]](#) [\[PubMed\]](#)
90. Kawakami, Y.; Eliyahu, S.; Jennings, C.; Sakaguchi, K.; Kang, X.; Southwood, S.; Robbins, P.F.; Sette, A.; Appella, E.; Rosenberg, S.A. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. *J. Immunol.* **1995**, *154*, 3961–3968. [\[CrossRef\]](#) [\[PubMed\]](#)
91. Bakker, A.B.; Schreurs, M.W.; Tafazzul, G.; de Boer, A.J.; Kawakami, Y.; Adema, G.J.; Figdor, C.G. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. *Int. J. Cancer* **1995**, *62*, 97–102. [\[CrossRef\]](#) [\[PubMed\]](#)
92. Schwartzentruber, D.J.; Lawson, D.H.; Richards, J.M.; Conry, R.M.; Miller, D.M.; Treisman, J.; Gailani, F.; Riley, L.; Conlon, K.; Pockaj, B.; et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N. Engl. J. Med.* **2011**, *364*, 2119–2127. [\[CrossRef\]](#) [\[PubMed\]](#)
93. Nathan, P.; Hassel, J.C.; Rutkowski, P.; Baurain, J.F.; Butler, M.O.; Schlaak, M.; Sullivan, R.J.; Ochsenreither, S.; Dummer, R.; Kirkwood, J.M.; et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. *N. Engl. J. Med.* **2021**, *385*, 1196–1206. [\[CrossRef\]](#) [\[PubMed\]](#)
94. Safety and Efficacy of IMCgp100 Versus Investigator Choice in Uveal Melanoma. Available online: <https://clinicaltrials.gov/study/NCT03070392> (accessed on 10 August 2025).
95. FDA Approves Tebentafusp-Tebn for Unresectable or Metastatic Uveal Melanoma. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2022/761228Orig1s000ltr.pdf (accessed on 11 August 2025).
96. Hassel, J.C.; Piperno-Neumann, S.; Rutkowski, P.; Baurain, J.F.; Schlaak, M.; Butler, M.O.; Sullivan, R.J.; Dummer, R.; Kirkwood, J.M.; Orloff, M.; et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. *N. Engl. J. Med.* **2023**, *389*, 2256–2266. [\[CrossRef\]](#) [\[PubMed\]](#)

97. Piulats, J.M.; Watkins, C.; Costa-Garcia, M.; Del Carpio, L.; Piperno-Neumann, S.; Rutkowski, P.; Hassel, J.C.; Espinosa, E.; de la Cruz-Merino, L.; Ochsenreither, S.; et al. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis. *Ann. Oncol.* **2024**, *35*, 317–326. [[CrossRef](#)] [[PubMed](#)]
98. van Essen, T.H.; Bronkhorst, I.H.; Maat, W.; Verduyn, W.; Roelen, D.L.; Luyten, G.P.; Jager, M.J. A comparison of HLA genotype with inflammation in uveal melanoma. *Investig. Ophthalmol. Vis. Sci.* **2012**, *53*, 2640–2646. [[CrossRef](#)] [[PubMed](#)]
99. Zhang, Z.; Yang, X. Design and synthesis of BAP-1 inhibitors. *Pak. J. Pharm. Sci.* **2026**, *39*, 1175–1184. [[CrossRef](#)] [[PubMed](#)]
100. Ge, Y.; Deng, J.J.; Zhu, J.; Liu, L.; Ouyang, S.; Song, Z.; Zhang, X.; Xiong, X.F. Discovery of small molecule Galphaq/11 protein inhibitors against uveal melanoma. *Acta Pharm. Sin. B* **2022**, *12*, 3326–3340. [[CrossRef](#)] [[PubMed](#)]
101. Schrage, R.; Schmitz, A.L.; Gaffal, E.; Annala, S.; Kehraus, S.; Wenzel, D.; Bullesbach, K.M.; Bald, T.; Inoue, A.; Shinjo, Y.; et al. The experimental power of FR900359 to study Gq-regulated biological processes. *Nat. Commun.* **2015**, *6*, 10156. [[CrossRef](#)] [[PubMed](#)]
102. Xiong, X.F.; Zhang, H.; Underwood, C.R.; Harpsoe, K.; Gardella, T.J.; Woldike, M.F.; Mannstadt, M.; Gloriam, D.E.; Brauner-Osborne, H.; Stromgaard, K. Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors. *Nat. Chem.* **2016**, *8*, 1035–1041. [[CrossRef](#)] [[PubMed](#)]
103. Kostenis, E.; Pfeil, E.M.; Annala, S. Heterotrimeric G_q proteins as therapeutic targets? *J. Biol. Chem.* **2020**, *295*, 5206–5215. [[CrossRef](#)] [[PubMed](#)]
104. Ge, Y.; Shi, S.; Deng, J.J.; Chen, X.P.; Song, Z.; Liu, L.; Lou, L.; Zhang, X.; Xiong, X.F. Design, Synthesis, and Evaluation of Small Molecule Galphaq/11 Protein Inhibitors for the Treatment of Uveal Melanoma. *J. Med. Chem.* **2021**, *64*, 3131–3152. [[CrossRef](#)] [[PubMed](#)]
105. Schmitz, A.L.; Schrage, R.; Gaffal, E.; Charpentier, T.H.; Wiest, J.; Hiltensperger, G.; Morschel, J.; Hennen, S.; Haussler, D.; Horn, V.; et al. A cell-permeable inhibitor to trap Galphaq proteins in the empty pocket conformation. *Chem. Biol.* **2014**, *21*, 890–902. [[CrossRef](#)] [[PubMed](#)]
106. Onken, M.D.; Makepeace, C.M.; Kaltenbronn, K.M.; Choi, J.; Hernandez-Aya, L.; Weilbaecher, K.N.; Piggott, K.D.; Rao, P.K.; Yuede, C.M.; Dixon, A.J.; et al. Targeting primary and metastatic uveal melanoma with a G protein inhibitor. *J. Biol. Chem.* **2021**, *296*, 100403. [[CrossRef](#)] [[PubMed](#)]
107. Carlino, M.S.; Kapiteijn, E.; Piperno-Neumann, S.; Sullivan, R.J.; Carvajal, R.; Dummer, R.; Gromke, T.; Hassel, J.C.; Kee, D.; Ramelyte, E.; et al. An anti-PMEL antibody-drug conjugate with a G_q/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: A phase 1 trial. *Nat. Med.* **2026**. [[CrossRef](#)] [[PubMed](#)]
108. Wk, J.; D'Alessio, J.A.; Yerramilli-Rao, P.; Blankenship, J.; Buntin, K.; Burger, M.; Chen, Z.; Cho, Y.S.; Davis, J.; Ebel, N.; et al. Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq/11-specific inhibitor for the treatment of metastatic uveal melanoma. *Mol. Cancer Ther.* **2024**, *23*, IA022. [[CrossRef](#)]
109. Riese, D.J., 2nd; Stern, D.F. Specificity within the EGF family/ErbB receptor family signaling network. *Bioessays* **1998**, *20*, 41–48. [[CrossRef](#)]
110. Filardo, E.J. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer. *J. Steroid Biochem. Mol. Biol.* **2002**, *80*, 231–238. [[CrossRef](#)] [[PubMed](#)]
111. Blobel, C.P.; Carpenter, G.; Freeman, M. The role of protease activity in ErbB biology. *Exp. Cell Res.* **2009**, *315*, 671–682. [[CrossRef](#)] [[PubMed](#)]
112. Arteaga, C.L.; Engelman, J.A. ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. *Cancer Cell* **2014**, *25*, 282–303. [[CrossRef](#)] [[PubMed](#)]
113. Palanisamy, S.; Xue, C.; Ishiyama, S.; Naga Prasad, S.V.; Gabrielson, K. GPCR-ErbB transactivation pathways and clinical implications. *Cell Signal.* **2021**, *86*, 110092. [[CrossRef](#)] [[PubMed](#)]
114. Lucas, L.M.; Dwivedi, V.; Senfeld, J.I.; Cullum, R.L.; Mill, C.P.; Piazza, J.T.; Bryant, I.N.; Cook, L.J.; Miller, S.T.; Lott, J.H.t.; et al. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein. *Pharmacol. Rev.* **2022**, *74*, 18–47. [[CrossRef](#)] [[PubMed](#)]
115. Fischer, O.M.; Hart, S.; Gschwind, A.; Ullrich, A. EGFR signal transactivation in cancer cells. *Biochem. Soc. Trans.* **2003**, *31*, 1203–1208. [[CrossRef](#)] [[PubMed](#)]
116. Higashiyama, S.; Nanba, D. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. *Biochim. Biophys. Acta* **2005**, *1751*, 110–117. [[CrossRef](#)] [[PubMed](#)]
117. Mill, C.P.; Chester, J.A.; Riese, D.J., 2nd. EGFR may couple moderate alcohol consumption to increased breast cancer risk. *Breast Cancer* **2009**, *1*, 31–38. [[CrossRef](#)] [[PubMed](#)]
118. Ohtsu, H.; Dempsey, P.J.; Eguchi, S. ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. *Am. J. Physiol. Cell Physiol.* **2006**, *291*, C1–10. [[CrossRef](#)] [[PubMed](#)]
119. Wilson, K.J.; Gilmore, J.L.; Foley, J.; Lemmon, M.A.; Riese, D.J., 2nd. Functional selectivity of EGF family peptide growth factors: Implications for cancer. *Pharmacol. Ther.* **2009**, *122*, 1–8. [[CrossRef](#)] [[PubMed](#)]
120. George, A.J.; Hannan, R.D.; Thomas, W.G. Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches. *FEBS J.* **2013**, *280*, 5258–5268. [[CrossRef](#)] [[PubMed](#)]

121. Kose, M. GPCRs and EGFR—Cross-talk of membrane receptors in cancer. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 3611–3620. [[CrossRef](#)] [[PubMed](#)]
122. Tito, C.; Masciarelli, S.; Colotti, G.; Fazi, F. EGF receptor in organ development, tissue homeostasis and regeneration. *J. Biomed. Sci.* **2025**, *32*, 24. [[CrossRef](#)] [[PubMed](#)]
123. Topalan, E.; Buyukgungor, A.; Cigdem, M.; Gura, S.; Sever, B.; Otsuka, M.; Fujita, M.; Demirci, H.; Ciftci, H. A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non-Small Cell Lung Cancer. *Arch. Pharm.* **2025**, *358*, e2400992. [[CrossRef](#)] [[PubMed](#)]
124. Segers, V.F.M.; Dugaucquier, L.; Feyen, E.; Shakeri, H.; De Keulenaer, G.W. The role of ErbB4 in cancer. *Cell. Oncol.* **2020**, *43*, 335–352. [[CrossRef](#)] [[PubMed](#)]
125. Wang, Z. ErbB Receptors and Cancer. *Methods Mol. Biol.* **2017**, *1652*, 3–35. [[CrossRef](#)] [[PubMed](#)]
126. Stern, D.F. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. *J. Mammary Gland Biol. Neoplasia* **2008**, *13*, 215–223. [[CrossRef](#)] [[PubMed](#)]
127. Trombetta, D.; Fabrizio, F.P.; Di Maio, M.; Parente, P.; Melocchi, L.; Martini, M.; Sparaneo, A.; Latiano, T.P.; Graziano, P.; Rossi, G.; et al. NRG/ErbB signaling: On the trail of a molecular fingerprint in mucinous carcinoma. *Expert Opin. Ther. Targets* **2025**, *29*, 423–434. [[CrossRef](#)] [[PubMed](#)]
128. Zhao, J.; Xu, W.; Zhou, F.; Zhang, X.; Zhou, M.; Miao, D.; Yu, L.; Zhang, Y.; Fan, J.; Zhou, C.; et al. Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC—Mechanisms and evolving treatment approaches. *Nat. Rev. Clin. Oncol.* **2026**, *23*, 63–83. [[CrossRef](#)] [[PubMed](#)]
129. Zhang, Y.C.; Luo, W.C.; Li, J.T.; Wu, L.; Chen, Z.H.; Zhou, Q. The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors. *J. Control. Release* **2026**, *393*, 114747. [[CrossRef](#)] [[PubMed](#)]
130. Ali, S.; Ilyas, A.; Nazar, S.; Jha, M.; Mathur, V.; Tanweer, S.; Grover, S.; Alam, O. EGFR-targeted tyrosine kinase inhibitors: Advancements in cancer therapy. *Naunyn Schmiedeberg's Arch. Pharmacol.* **2026**, *399*, 4737–4754. [[CrossRef](#)] [[PubMed](#)]
131. Ding, C.; Yao, R.; Wang, Y.; Liu, H.; Li, C.; Xie, H. An overview of mechanisms, biomarkers, and treatment strategies for acquired anti-EGFR resistance in RAS wild-type colorectal cancer. *Front. Pharmacol.* **2025**, *16*, 1656372. [[CrossRef](#)] [[PubMed](#)]
132. Al-Awadhi, S.S.A.; Patil, P.; Shetty, P.; Shetty, P.K.; Shetty, R.A.; Shetty, V.V. Potential role of epidermal growth factor receptors (EGFR) signaling in the pathogenesis and management of hepatocellular carcinoma. *Bioimpacts* **2025**, *15*, 30905. [[CrossRef](#)] [[PubMed](#)]
133. Deng, S.; Sun, C.; Liu, D.; Zhang, Y.; Zhang, J.; Li, X.; Jia, X.; Kai, G. Antibody-drug conjugates: A new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer. *Pharmacol. Res.* **2026**, *223*, 108066. [[CrossRef](#)] [[PubMed](#)]
134. Vitiello, P.P.; Saoudi Gonzalez, N.; Bardelli, A. When molecular biology transforms clinical oncology: The EGFR journey in colorectal cancer. *Mol. Oncol.* **2025**, *19*, 267–270. [[CrossRef](#)] [[PubMed](#)]
135. Singh, G.; Rohit; Kumar, P.; Aran, K.R. Targeting EGFR and PI3K/mTOR pathways in glioblastoma: Innovative therapeutic approaches. *Med. Oncol.* **2025**, *42*, 97. [[CrossRef](#)] [[PubMed](#)]
136. Joshi, H.; Sheikh, M.S. Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR-Mutant Lung Cancer. *Cancers* **2025**, *17*, 2791. [[CrossRef](#)] [[PubMed](#)]
137. Du, Y.; Karatekin, F.; Wang, W.K.; Hong, W.; Boopathy, G.T.K. Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers. *Pharmacol. Rev.* **2025**, *77*, 100076. [[CrossRef](#)] [[PubMed](#)]
138. Moody, T.W.; Nuche-Berenguer, B.; Nakamura, T.; Jensen, R.T. EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer. *Curr. Drug Targets* **2016**, *17*, 520–528. [[CrossRef](#)] [[PubMed](#)]
139. Wilson, K.J.; Mill, C.; Lambert, S.; Buchman, J.; Wilson, T.R.; Hernandez-Gordillo, V.; Gallo, R.M.; Ades, L.M.; Settleman, J.; Riese, D.J., 2nd. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. *Growth Factors* **2012**, *30*, 107–116. [[CrossRef](#)] [[PubMed](#)]
140. Citri, A.; Yarden, Y. EGF-ERBB signalling: Towards the systems level. *Nat. Rev. Mol. Cell Biol.* **2006**, *7*, 505–516. [[CrossRef](#)] [[PubMed](#)]
141. Wang, W.; Zhao, H.F.; Yao, T.F.; Gong, H. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment. *Investig. New Drugs* **2019**, *37*, 175–183. [[CrossRef](#)] [[PubMed](#)]
142. Kazanietz, M.G.; Barrio-Real, L.; Casado-Medrano, V.; Baker, M.J.; Lopez-Haber, C. The P-Rex1/Rac signaling pathway as a point of convergence for HER/ErbB receptor and GPCR responses. *Small GTPases* **2018**, *9*, 297–303. [[CrossRef](#)] [[PubMed](#)]
143. Gottesdiener, L.S.; O'Connor, S.; Busam, K.J.; Won, H.; Solit, D.B.; Hyman, D.M.; Shoushtari, A.N. Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma. *Clin. Cancer Res.* **2018**, *24*, 5815–5819. [[CrossRef](#)] [[PubMed](#)]
144. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. *Nat. Rev. Mol. Cell Biol.* **2001**, *2*, 127–137. [[CrossRef](#)] [[PubMed](#)]

145. Mukherjee, A.G.; Gopalakrishnan, A.V. HER2 as a molecular trojan horse in prostate cancer: Mechanistic insights and therapeutic unlocks. *Mol. Biol. Rep.* **2025**, *53*, 31. [\[CrossRef\]](#) [\[PubMed\]](#)
146. Arienti, C.; Pignatta, S.; Tesei, A. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. *Front. Oncol.* **2019**, *9*, 1308. [\[CrossRef\]](#) [\[PubMed\]](#)
147. Xie, Z.; Chen, X.; Gao, R.; Yang, M.; Han, X.; Sun, Y.; Shi, Y. Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997–2026). *Chin. Med. J.* **2026**, *139*, 973–1007. [\[CrossRef\]](#) [\[PubMed\]](#)
148. Carosi, F.; Filippini, D.M.; Fabbri, L.; Carlini, A.; Monte, A.; Sgarzi, M.; Fermi, M.; Querzoli, G.; Romaniello, D.; Mercante, G.; et al. Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers. *Crit. Rev. Oncol. Hematol.* **2026**, *221*, 105207. [\[CrossRef\]](#) [\[PubMed\]](#)
149. Spitaleri, G.; Trillo Aliaga, P.; Mariani, G.A.; Attili, I.; Del Signore, E.; Corvaja, C.; Napoli, V.M.; Cavallone, M.; Etessami, J.D.; Zhan, Y.; et al. Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): ‘Where the streets have no name’. *Crit. Rev. Oncol. Hematol.* **2026**, *223*, 105327. [\[CrossRef\]](#) [\[PubMed\]](#)
150. Dutta, S.; Rajesh, R.; Gurubasavaraja Swamy, P.M.; Paik, A.; Dasgupta, A.; Pal, R.; Kushal, J.; Pavani, G. Medicinal chemistry perspective on quinazoline derivatives: Sustainable synthetic routes, anticancer evaluation, and SAR analysis. *Eur. J. Med. Chem.* **2026**, *304*, 118538. [\[CrossRef\]](#) [\[PubMed\]](#)
151. Liu, Z.; Kim, M.O. From Gefitinib to Amivantamab: Progress and Perspectives of Therapies Targeting the Epidermal Growth Factor Receptor in the Era of Precision Oncology. *J. Cancer Prev.* **2026**, *31*, 11–19. [\[CrossRef\]](#) [\[PubMed\]](#)
152. Berg, J.M.; Viray, H.; Green, J.; VanderLaan, P.A.; Kobayashi, S.S.; Le, X.; Costa, D.B.; Rangachari, D. Lung cancer with EGFR PACC mutations: A practical review of available treatment options and novel therapies on the horizon. *Transl. Lung Cancer Res.* **2026**, *15*, 144. [\[CrossRef\]](#) [\[PubMed\]](#)
153. Jangra, N.; Sharma, B.; Kumar, D.; Kapoor, A. A momentous progress update: Epidermal growth factor receptor inhibitors as viable agents for combating cancer. *RSC Med. Chem.* **2025**, *16*, 3893–3958. [\[CrossRef\]](#) [\[PubMed\]](#)
154. Wang, C.; Xiao, D.; Zhai, C. Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and network meta-analysis. *BMC Cancer* **2025**, *25*, 1072. [\[CrossRef\]](#) [\[PubMed\]](#)
155. Suryawanshi, M.V.; Girase, R.T.; Bagul, V.S.; Gujarathi, P.P. Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: Comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies. *Clin. Transl. Oncol.* **2026**. [\[CrossRef\]](#) [\[PubMed\]](#)
156. Chen, W.; Wang, R.; Lin, Y.; Wang, X.; Cai, F.; Lin, M.; Wang, J.; Zhang, H.; Chen, M. The antibreast cancer therapeutic potential of quinazoline hybrids-Part I. *Future Med. Chem.* **2025**, *17*, 1055–1069. [\[CrossRef\]](#) [\[PubMed\]](#)
157. Zeng, H.; Zhuang, M.; Cai, F.; Lin, M.; Wang, R.; Wang, J.; Zhang, H. The current status of quinazoline hybrids with antibreast cancer therapeutic potential-part II. *Future Med. Chem.* **2025**, *17*, 1457–1469. [\[CrossRef\]](#) [\[PubMed\]](#)
158. Sokol, M.K.; Ha, J.H.; Li, G.; Kim, L.H. A review of targeted therapies for NF2-related vestibular schwannoma: Molecular pathogenesis, emerging therapeutics, and future clinical horizons. *J. Neuro-Oncol.* **2026**, *178*, 1. [\[CrossRef\]](#) [\[PubMed\]](#)
159. Maione, P.; Romano, F.J.; Gridelli, C. Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option? *Curr. Oncol.* **2026**, *33*, 54. [\[CrossRef\]](#) [\[PubMed\]](#)
160. Abdayem, P.; Parisi, C.; Planchard, D. First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient? *Drugs* **2026**, *86*, 335–357. [\[CrossRef\]](#) [\[PubMed\]](#)
161. Jin, Z.; Yuan, L.; Ma, Y.; Ye, Z.; Zhang, Z.; Wang, Y.; Hu, C.; Dong, J.; Zhang, X.; Xu, Z.; et al. A comprehensive proteomic analysis uncovers novel molecular subtypes of gastric signet ring cell carcinoma: Identification of potential prognostic biomarkers and therapeutic targets. *Genes. Dis.* **2026**, *13*, 101717. [\[CrossRef\]](#) [\[PubMed\]](#)
162. Zhao, S.; Liu, X.; Wang, J.; Tang, B.; Long, Q.; Tang, X.; Dai, J.; Jiang, Y.; Liu, Q. Perioperative strategies for resectable EGFR-Mutant NSCLC: Evidence hierarchy and clinical decision-making. *Cancer Treat. Rev.* **2026**, *146*, 103138. [\[CrossRef\]](#)
163. Mayuri, M.; Reddy Kandula, S.; Ramakrishna, V.; Sanka, P.; Sidde, G.P.; Muzzamil, S.M.; Uppara, H.B.; Prasad, P.D. Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer. *Int. J. Cancer* **2026**, *158*, 2512–2519. [\[CrossRef\]](#)
164. Keam, S.J. Sevakertinib: First Approval. *Drugs* **2026**, *86*, 759–764. [\[CrossRef\]](#)
165. Richani Meinhardt, F.W.; Zambrano Iglesias, M.I.; Fernandez Gomez, M.P.; Saltaren Fonseca, J.F.; Hussein, A.; Raez, L.E. HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC). *Int. J. Mol. Sci.* **2026**, *27*, 4910. [\[CrossRef\]](#)
166. Balli, S.; Basoglu, T.; Ozdogan, M. Evolving treatment strategies for HER2-altered non-small-cell lung cancer: The rise of TKIs and ADCs. *Front. Oncol.* **2026**, *16*, 1771869. [\[CrossRef\]](#)
167. Muscolino, P.; Fassi, E.; Signorelli, D.; Colonese, F.; Cortinovis, D.L.; Lo Russo, G.; Pasello, G.; Infurna, C.; Ciappina, G.; Berretta, M.; et al. HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape. *Int. J. Mol. Sci.* **2026**, *27*, 2334. [\[CrossRef\]](#) [\[PubMed\]](#)

168. Del Rio, B.; Masini, S.; Caceres-Galvis, C.; Torres-Jimenez, J.; Bote, H.; Zurera, M.; Baena, J.; Serrano, C.; Nunez, J.A.; Ponce-Aix, S.; et al. Emerging Targeted Therapies for HER2-Mutant NSCLC. *J. Thorac. Oncol.* **2026**, 103899. [CrossRef] [PubMed]
169. Chang, L.; Wang, M.; Zhang, H.; Li, Z.; Song, Z.; Zhao, L.; Jiang, F.; Wang, J.; Quan, Y. Synthesis and Clinical Application of Small-Molecule Drugs Approved by FDA in 2025. *Med. Res. Rev.* **2026**. [CrossRef] [PubMed]
170. Goto, K.; Hayashi, H.; Maruti, S.S.; Zettl, H.; Mittal, L.; Pathak, S.; Le, X. Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review. *Target. Oncol.* **2026**, 21, 337–356. [CrossRef] [PubMed]
171. Rosas, D.; Desai, J.; Raez, L. Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy. *Int. J. Mol. Sci.* **2026**, 27, 3714. [CrossRef] [PubMed]
172. Zhou, C.; Greillier, L.; Liu, G.; John, T.; Xing, L.; Kowalski, D.; Memmott, R.M.; Yazici, O.; Sun, M.; Shu, C.; et al. First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. *N. Engl. J. Med.* **2026**. [CrossRef] [PubMed]
173. Roskoski, R., Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update. *Pharmacol. Res.* **2026**, 224, 108107. [CrossRef] [PubMed]
174. Hoyek, C.; Zheng-Lin, B.; Jones, J.; Bekaii-Saab, T. Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: Current insights and future prospects. *Expert Opin. Investig. Drugs* **2025**, 34, 161–168. [CrossRef] [PubMed]
175. Shagisultanova, E.; Parris, H.; Liu, L.; Giangiuli, S.; Gao, D.; Diamond, J.R.; Acharya-Leon, R.; Kabos, P.; Borges, V.F. Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer. *Clin. Breast Cancer* **2025**, 25, 643–649.e641. [CrossRef] [PubMed]
176. De, A.; Dey, P.; Bishnu, A.; Patel, J.; Mishra, S.; Gadewal, N.; Ray, P.; Gupta, S. Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure. *Res. Sq.* **2025**. [CrossRef] [PubMed]
177. Kim, J.; Ahn, M.J. Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer. *Future Oncol.* **2026**, 22, 1281–1289. [CrossRef] [PubMed]
178. Amaro, A.; Mirisola, V.; Angelini, G.; Musso, A.; Tosetti, F.; Esposito, A.I.; Perri, P.; Lanza, F.; Nasciuti, F.; Mosci, C.; et al. Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity. *Eur. J. Cancer* **2013**, 49, 3353–3365. [CrossRef] [PubMed]
179. Boone, B.; Jacobs, K.; Ferdinande, L.; Taideman, J.; Lambert, J.; Peeters, M.; Bracke, M.; Pauwels, P.; Brochez, L. EGFR in melanoma: Clinical significance and potential therapeutic target. *J. Cutan. Pathol.* **2011**, 38, 492–502. [CrossRef] [PubMed]
180. Abbas, N.; Mourad, M.; Smaily, H.; Al Mahmasani, L.; Shamseddine, A. EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance. *Int. J. Mol. Sci.* **2026**, 27, 3265. [CrossRef] [PubMed]
181. Santos, E.D.S.; Nogueira, K.A.B.; Fernandes, L.C.C.; Martins, J.R.P.; Reis, A.V.F.; Neto, J.B.V.; Junior, I.; Pessoa, C.; Petrilli, R.; Eloy, J.O. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. *Int. J. Pharm.* **2021**, 592, 120082. [CrossRef] [PubMed]
182. Cai, W.Q.; Zeng, L.S.; Wang, L.F.; Wang, Y.Y.; Cheng, J.T.; Zhang, Y.; Han, Z.W.; Zhou, Y.; Huang, S.L.; Wang, X.W.; et al. The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. *Front. Oncol.* **2020**, 10, 1249. [CrossRef] [PubMed]
183. Diaz-Serrano, A.; Sanchez-Torre, A.; Paz-Ares, L. Necitumumab for the treatment of advanced non-small-cell lung cancer. *Future Oncol.* **2019**, 15, 705–716. [CrossRef] [PubMed]
184. Allu, S.; Saravanan, Y.; Sakthivel, K.M.; Chinnadurai, K.; Kumar, P.; Saravanan, M.; Rasmi, R.R. Decoding the Genetic Hallmarks of Breast Cancer: Molecular Signatures, Prognostic and Therapeutic Perspectives. *Appl. Biochem. Biotechnol.* **2026**. [CrossRef] [PubMed]
185. Esen, S.A.; Uncu, D.; Sendur, M.A.N. Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies. *Expert Opin. Drug Saf.* **2026**, 1–10. [CrossRef] [PubMed]
186. Kawczak, P.; Baczek, T. Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib. *J. Clin. Med.* **2026**, 15, 2387. [CrossRef] [PubMed]
187. Wan, G.; Yang, L.; Wang, Q.; Xu, G. T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: Preclinical evaluation and mechanisms, prediction, and exploration of adverse effects. *Discov. Oncol.* **2025**, 16, 857. [CrossRef] [PubMed]
188. Riese, D.J., 2nd. EGF Binding and EGFR Dimerization. Available online: <https://BioRender.com/gcswiuw> (accessed on 19 July 2026).
189. Tao, Z.; Shao, W.; Zhou, H.; Xia, S.; Zeng, J.; Ren, J.; Wang, X.; Zhu, H. Role of signaling pathways in lung cancer development and advances in targeted therapies (Review). *Oncol. Lett.* **2025**, 30, 589. [CrossRef] [PubMed]
190. Riese, D.J., 2nd. ERBB Receptor Trans-Phosphorylation. Available online: <https://BioRender.com/xj19yq8> (accessed on 19 July 2026).
191. Riese, D.J., 2nd. Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery? *Expert Opin. Drug Discov.* **2011**, 6, 185–193. [CrossRef] [PubMed]

192. Burke, C.L.; Lemmon, M.A.; Coren, B.A.; Engelman, D.M.; Stern, D.F. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. *Oncogene* **1997**, *14*, 687–696. [[CrossRef](#)] [[PubMed](#)]
193. Burke, C.L.; Stern, D.F. Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface. *Mol. Cell. Biol.* **1998**, *18*, 5371–5379. [[CrossRef](#)] [[PubMed](#)]
194. Wilson, K.J.; Mill, C.P.; Cameron, E.M.; Hobbs, S.S.; Hammer, R.P.; Riese, D.J., 2nd. Inter-conversion of neuregulin2 full and partial agonists for ErbB4. *Biochem. Biophys. Res. Commun.* **2007**, *364*, 351–357. [[CrossRef](#)] [[PubMed](#)]
195. Wilson, K.J.; Mill, C.P.; Gallo, R.M.; Cameron, E.M.; VanBrocklin, H.; Settleman, J.; Riese, D.J. The Q43L mutant of neuregulin 2beta is a pan-ErbB receptor antagonist. *Biochem. J.* **2012**, *443*, 133–144. [[CrossRef](#)] [[PubMed](#)]
196. Hu, C.; Leche, C.A., 2nd; Kiyatkin, A.; Yu, Z.; Staybrook, S.E.; Ferguson, K.M.; Lemmon, M.A. Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias. *Nature* **2022**, *602*, 518–522. [[CrossRef](#)] [[PubMed](#)]
197. Gaba, S.; Sahu, M.; Chauhan, N.; Jain, U. Transforming growth factor alpha: Key insights into physiological role, cancer therapeutics, and biomarker potential (A review). *Int. J. Biol. Macromol.* **2025**, *310*, 143212. [[CrossRef](#)] [[PubMed](#)]
198. Freed, D.M.; Bessman, N.J.; Kiyatkin, A.; Salazar-Cavazos, E.; Byrne, P.O.; Moore, J.O.; Valley, C.C.; Ferguson, K.M.; Leahy, D.J.; Lidke, D.S.; et al. EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics. *Cell* **2017**, *171*, 683–695.e618. [[CrossRef](#)] [[PubMed](#)]
199. Desai, O.; Rathore, M.; Boutros, C.S.; Wright, M.; Bryson, E.; Curry, K.; Wang, R. HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway. *Genes. Dis.* **2025**, *12*, 101354. [[CrossRef](#)] [[PubMed](#)]
200. Ergun, Y. HER3 in breast cancer: Molecular insights, clinical implications, and therapeutic horizons. *Expert Opin. Ther. Targets* **2025**, *29*, 481–489. [[CrossRef](#)] [[PubMed](#)]
201. Garrett, J.T.; Tendler, S.; Feroz, W.; Kilroy, M.K.; Yu, H. Emerging importance of HER3 in tumorigenesis and cancer therapy. *Nat. Rev. Clin. Oncol.* **2025**, *22*, 348–370. [[CrossRef](#)] [[PubMed](#)]
202. Pitfield, S.E.; Bryant, I.; Penington, D.J.; Park, G.; Riese, D.J., 2nd. Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. *Oncol. Res.* **2006**, *16*, 179–193. [[CrossRef](#)] [[PubMed](#)]
203. Mill, C.P.; Gettinger, K.L.; Riese, D.J., 2nd. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. *Exp. Cell Res.* **2011**, *317*, 392–404. [[CrossRef](#)] [[PubMed](#)]
204. Mill, C.P.; Zordan, M.D.; Rothenberg, S.M.; Settleman, J.; Leary, J.F.; Riese, D.J., 2nd. ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer. *Genes Cancer* **2011**, *2*, 792–804. [[CrossRef](#)] [[PubMed](#)]
205. Gilmore, J.L.; Gonterman, R.M.; Menon, K.; Lorch, G.; Riese, D.J., 2nd; Robling, A.; Foley, J. Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone. *Mol. Cancer Res.* **2009**, *7*, 1714–1728. [[CrossRef](#)] [[PubMed](#)]
206. Gilmore, J.L.; Scott, J.A.; Bouizar, Z.; Robling, A.; Pitfield, S.E.; Riese, D.J., 2nd; Foley, J. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. *Breast Cancer Res. Treat.* **2008**, *110*, 493–505. [[CrossRef](#)] [[PubMed](#)]
207. Zhou, W.; Carpenter, G. Heregulin-dependent trafficking and cleavage of ErbB-4. *J. Biol. Chem.* **2000**, *275*, 34737–34743. [[CrossRef](#)] [[PubMed](#)]
208. Ni, C.Y.; Murphy, M.P.; Golde, T.E.; Carpenter, G. gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. *Science* **2001**, *294*, 2179–2181. [[CrossRef](#)] [[PubMed](#)]
209. Carpenter, G. ErbB-4: Mechanism of action and biology. *Exp. Cell Res.* **2003**, *284*, 66–77. [[CrossRef](#)] [[PubMed](#)]
210. Carpenter, G. Nuclear localization and possible functions of receptor tyrosine kinases. *Curr. Opin. Cell Biol.* **2003**, *15*, 143–148. [[CrossRef](#)] [[PubMed](#)]
211. Schlessinger, J.; Lemmon, M.A. Nuclear signaling by receptor tyrosine kinases: The first robin of spring. *Cell* **2006**, *127*, 45–48. [[CrossRef](#)] [[PubMed](#)]
212. Gilmore, J.L.; Riese, D.J., 2nd. secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. *Oncol. Res.* **2004**, *14*, 589–602. [[CrossRef](#)] [[PubMed](#)]
213. Lee, H.J.; Jung, K.M.; Huang, Y.Z.; Bennett, L.B.; Lee, J.S.; Mei, L.; Kim, T.W. Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. *J. Biol. Chem.* **2002**, *277*, 6318–6323. [[CrossRef](#)] [[PubMed](#)]
214. Linggi, B.; Carpenter, G. ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression. *J. Biol. Chem.* **2006**, *281*, 25373–25380. [[CrossRef](#)] [[PubMed](#)]
215. Naresh, A.; Long, W.; Vidal, G.A.; Wimley, W.C.; Marrero, L.; Sartor, C.I.; Tovey, S.; Cooke, T.G.; Bartlett, J.M.; Jones, F.E. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. *Cancer Res.* **2006**, *66*, 6412–6420. [[CrossRef](#)] [[PubMed](#)]
216. Letai, A.; Bassik, M.C.; Walensky, L.D.; Sorcinelli, M.D.; Weiler, S.; Korsmeyer, S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. *Cancer Cell* **2002**, *2*, 183–192. [[CrossRef](#)] [[PubMed](#)]

217. Williams, C.C.; Allison, J.G.; Vidal, G.A.; Burow, M.E.; Beckman, B.S.; Marrero, L.; Jones, F.E. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. *J. Cell Biol.* **2004**, *167*, 469–478. [\[CrossRef\]](#) [\[PubMed\]](#)
218. Heery, D.M.; Kalkhoven, E.; Hoare, S.; Parker, M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. *Nature* **1997**, *387*, 733–736. [\[CrossRef\]](#) [\[PubMed\]](#)
219. Veikkolainen, V.; Vaparenta, K.; Halkilahti, K.; Iljin, K.; Sundvall, M.; Elenius, K. Function of ERBB4 is determined by alternative splicing. *Cell Cycle* **2011**, *10*, 2647–2657. [\[CrossRef\]](#) [\[PubMed\]](#)
220. Vazquez-Cuevas, F.G.; Reyna-Jeldes, M.; Velazquez-Miranda, E.; Coddou, C. Transactivation of receptor tyrosine kinases by purinergic P2Y and adenosine receptors. *Purinergic Signal.* **2023**, *19*, 613–621. [\[CrossRef\]](#) [\[PubMed\]](#)
221. Wang, W.; Qiao, Y.; Li, Z. New Insights into Modes of GPCR Activation. *Trends Pharmacol. Sci.* **2018**, *39*, 367–386. [\[CrossRef\]](#) [\[PubMed\]](#)
222. Kilpatrick, L.E.; Hill, S.J. Transactivation of G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs): Recent insights using luminescence and fluorescence technologies. *Curr. Opin. Endocr. Metab. Res.* **2021**, *16*, 102–112. [\[CrossRef\]](#) [\[PubMed\]](#)
223. New, D.C.; Wong, Y.H. Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. *J. Mol. Signal.* **2007**, *2*, 2. [\[CrossRef\]](#) [\[PubMed\]](#)
224. Heppner, D.E.; van der Vliet, A. Redox-dependent regulation of epidermal growth factor receptor signaling. *Redox Biol.* **2016**, *8*, 24–27. [\[CrossRef\]](#) [\[PubMed\]](#)
225. Wang, Z. Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research. *Int. J. Mol. Sci.* **2016**, *17*, 95. [\[CrossRef\]](#) [\[PubMed\]](#)
226. Salazar, N.; Munoz, D.; Kallifatidis, G.; Singh, R.K.; Jorda, M.; Lokeshwar, B.L. The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation. *Mol. Cancer* **2014**, *13*, 198. [\[CrossRef\]](#) [\[PubMed\]](#)
227. Yoshisue, H.; Kirkham-Brown, J.; Healy, E.; Holgate, S.T.; Sampson, A.P.; Davies, D.E. Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts. *J. Allergy Clin. Immunol.* **2007**, *119*, 132–140. [\[CrossRef\]](#) [\[PubMed\]](#)
228. Riese, D.J., 2nd. GPCR-EGFR Crosstalk. Available online: <https://BioRender.com/p5kjeg9> (accessed on 30 December 2025).
229. Kamato, D.; Thach, L.; Bernard, R.; Chan, V.; Zheng, W.; Kaur, H.; Brimble, M.; Osman, N.; Little, P.J. Structure, Function, Pharmacology, and Therapeutic Potential of the G Protein, G α /q.11. *Front. Cardiovasc. Med.* **2015**, *2*, 14. [\[CrossRef\]](#) [\[PubMed\]](#)
230. Naor, Z.; Benard, O.; Seger, R. Activation of MAPK cascades by G-protein-coupled receptors: The case of gonadotropin-releasing hormone receptor. *Trends Endocrinol. Metab.* **2000**, *11*, 91–99. [\[CrossRef\]](#) [\[PubMed\]](#)
231. Nell, R.J.; Menger, N.V.; Versluis, M.; Luyten, G.P.M.; Verdijk, R.M.; Madigan, M.C.; Jager, M.J.; van der Velden, P.A. Involvement of mutant and wild-type *CYSLTR2* in the development and progression of uveal nevi and melanoma. *BMC Cancer* **2021**, *21*, 164. [\[CrossRef\]](#) [\[PubMed\]](#)
232. Ceraudo, E.; Horioka, M.; Mattheisen, J.M.; Hitchman, T.D.; Moore, A.R.; Kazmi, M.A.; Chi, P.; Chen, Y.; Sakmar, T.P.; Huber, T. Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. *J. Biol. Chem.* **2021**, *296*, 100163. [\[CrossRef\]](#) [\[PubMed\]](#)
233. Riechardt, A.I.; Kilic, E.; Joussen, A.M. The Genetics of Uveal Melanoma: Overview and Clinical Relevance. *Klin. Monbl. Augenheilkd.* **2021**, *238*, 773–780. [\[CrossRef\]](#) [\[PubMed\]](#)
234. Moore, A.R.; Ceraudo, E.; Sher, J.J.; Guan, Y.; Shoushtari, A.N.; Chang, M.T.; Zhang, J.Q.; Walczak, E.G.; Kazmi, M.A.; Taylor, B.S.; et al. Recurrent activating mutations of G-protein-coupled receptor *CYSLTR2* in uveal melanoma. *Nat. Genet.* **2016**, *48*, 675–680. [\[CrossRef\]](#) [\[PubMed\]](#)
235. Bol, K.F.; Donia, M.; Heegaard, S.; Kiilgaard, J.F.; Svane, I.M. Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. *Int. J. Mol. Sci.* **2020**, *21*, 5231. [\[CrossRef\]](#) [\[PubMed\]](#)
236. Johansson, P.; Aoude, L.G.; Wadt, K.; Glasson, W.J.; Warriar, S.K.; Hewitt, A.W.; Kiilgaard, J.F.; Heegaard, S.; Isaacs, T.; Franchina, M.; et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in *PLCB4*. *Oncotarget* **2016**, *7*, 4624–4631. [\[CrossRef\]](#) [\[PubMed\]](#)
237. Ma, J.; Weng, L.; Bastian, B.C.; Chen, X. Functional characterization of uveal melanoma oncogenes. *Oncogene* **2021**, *40*, 806–820. [\[CrossRef\]](#) [\[PubMed\]](#)
238. Phan, H.T.N.; Kim, N.H.; Wei, W.; Tall, G.G.; Smrcka, A.V. Uveal melanoma-associated mutations in *PLC β 4* are constitutively activating and promote melanocyte proliferation and tumorigenesis. *Sci. Signal.* **2021**, *14*, eabj4243. [\[CrossRef\]](#) [\[PubMed\]](#)
239. Ambrosini, G.; Musi, E.; Ho, A.L.; de Stanchina, E.; Schwartz, G.K. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death. *Mol. Cancer Ther.* **2013**, *12*, 768–776. [\[CrossRef\]](#) [\[PubMed\]](#)
240. Chen, X.; Wu, Q.; Depeille, P.; Chen, P.; Thornton, S.; Kalirai, H.; Coupland, S.E.; Roose, J.P.; Bastian, B.C. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. *Cancer Cell* **2017**, *31*, 685–696.e686. [\[CrossRef\]](#) [\[PubMed\]](#)

241. Shoushtari, A.N.; Kudchadkar, R.R.; Panageas, K.S.; Murthy, R.K.; Jung, M.; Shah, R.; O'Donnell, B.; Khawaja, T.T.; Shames, Y.; Prempeh-Keteku, N.A.; et al. A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma. *J. Clin. Oncol.* **2016**, *34*, 9511. [\[CrossRef\]](#)
242. Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma. Available online: <https://clinicaltrials.gov/study/NCT01979523?tab=results> (accessed on 26 December 2025).
243. Hitchman, T.D.; Bayshtok, G.; Ceraudo, E.; Moore, A.R.; Lee, C.; Jia, R.; Wang, N.; Pachai, M.R.; Shoushtari, A.N.; Francis, J.H.; et al. Combined Inhibition of G α_q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. *Clin. Cancer Res.* **2021**, *27*, 1476–1490. [\[CrossRef\]](#) [\[PubMed\]](#)
244. Piperno-Neumann, S.; Larkin, J.; Carvajal, R.D.; Luke, J.J.; Schwartz, G.K.; Hodi, F.S.; Sablin, M.P.; Shoushtari, A.N.; Szpakowski, S.; Chowdhury, N.R.; et al. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. *Mol. Cancer Ther.* **2020**, *19*, 1031–1039. [\[CrossRef\]](#) [\[PubMed\]](#)
245. Piperno-Neumann, S.; Carlino, M.S.; Boni, V.; Loirat, D.; Speetjens, F.M.; Park, J.J.; Calvo, E.; Carvajal, R.D.; Nyakas, M.; Gonzalez-Maffe, J.; et al. A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. *Br. J. Cancer* **2023**, *128*, 1040–1051. [\[CrossRef\]](#) [\[PubMed\]](#)
246. Chen, X.; Wu, Q.; Tan, L.; Porter, D.; Jager, M.J.; Emery, C.; Bastian, B.C. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. *Oncogene* **2014**, *33*, 4724–4734. [\[CrossRef\]](#) [\[PubMed\]](#)
247. Prabhu, K.S.; Kuttikrishnan, S.; Mariyam, Z.; Habeeba, U.; Panicker, A.J.; Masoodi, T.; Junejo, K.; Uddin, S. PI3 K/ AKT/ mTOR pathway and its role in breast cancer stem cells. *Naunyn Schmiedebergs Arch. Pharmacol.* **2025**, *398*, 16779–16795. [\[CrossRef\]](#) [\[PubMed\]](#)
248. Luo, J.; Li, H.; Xiu, J.; Zeng, J.; Feng, Z.; Zhao, H.; Li, Y.; Wei, W. Elevated ZNF704 expression is associated with poor prognosis of uveal melanoma and promotes cancer cell growth by regulating AKT/ mTOR signaling. *Biomark. Res.* **2023**, *11*, 38. [\[CrossRef\]](#) [\[PubMed\]](#)
249. Babchia, N.; Calipel, A.; Mouriaux, F.; Faussat, A.M.; Mascarelli, F. The PI3K/ Akt and mTOR/ P70S6K signaling pathways in human uveal melanoma cells: Interaction with B-Raf/ ERK. *Investig. Ophthalmol. Vis. Sci.* **2010**, *51*, 421–429. [\[CrossRef\]](#) [\[PubMed\]](#)
250. Smit, K.N.; Jager, M.J.; de Klein, A.; Kiliç, E. Uveal melanoma: Towards a molecular understanding. *Prog. Retin. Eye Res.* **2020**, *75*, 100800. [\[CrossRef\]](#) [\[PubMed\]](#)
251. Zhang, L.; Zhang, F.; Liang, H.; Qin, X.; Mo, Y.; Chen, S.; Xie, J.; Hou, X.; Deng, J.; Hao, E.; et al. Hippo/ YAP signaling pathway in colorectal cancer: Regulatory mechanisms and potential drug exploration. *Front. Oncol.* **2025**, *15*, 1545952. [\[CrossRef\]](#) [\[PubMed\]](#)
252. Zhang, J.; Wu, H.; Ren, X.; Chen, Z.; Ye, S.; Chen, S.; Fang, J.; Wu, Q.; Zhao, T. Hippo/ YAP signaling's multifaceted crosstalk in cancer. *Front. Cell Dev. Biol.* **2025**, *13*, 1595362. [\[CrossRef\]](#) [\[PubMed\]](#)
253. Yu, F.X.; Luo, J.; Mo, J.S.; Liu, G.; Kim, Y.C.; Meng, Z.; Zhao, L.; Peyman, G.; Ouyang, H.; Jiang, W.; et al. Mutant Gq/ 11 promote uveal melanoma tumorigenesis by activating YAP. *Cancer Cell* **2014**, *25*, 822–830. [\[CrossRef\]](#) [\[PubMed\]](#)
254. Feng, X.; Arang, N.; Rigracciolo, D.C.; Lee, J.S.; Yeerna, H.; Wang, Z.; Lubrano, S.; Kishore, A.; Pachter, J.A.; Konig, G.M.; et al. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. *Cancer Cell* **2019**, *35*, 457–472.e455. [\[CrossRef\]](#) [\[PubMed\]](#)
255. Li, H.; Li, Q.; Dang, K.; Ma, S.; Cotton, J.L.; Yang, S.; Zhu, L.J.; Deng, A.C.; Ip, Y.T.; Johnson, R.L.; et al. YAP/ TAZ Activation Drives Uveal Melanoma Initiation and Progression. *Cell Rep.* **2019**, *29*, 3200–3211.e3204. [\[CrossRef\]](#) [\[PubMed\]](#)
256. Djidjik, R.; Lamara Mahammed, L.; Berkani, L.M.; Allam, I.; Benmoussa, A.H.; Gharnaout, M.; Belaid, B. JAK/ STAT in human diseases: A common axis in immunodeficiencies and hematological disorders. *Front. Immunol.* **2025**, *16*, 1669688. [\[CrossRef\]](#) [\[PubMed\]](#)
257. Jia, J.; Zhou, X.; Chu, Q. Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer. *Mol. Cell Biochem.* **2025**, *480*, 1–17. [\[CrossRef\]](#) [\[PubMed\]](#)
258. Parveen, S.; Fatma, M.; Mir, S.S.; Dermime, S.; Uddin, S. JAK-STAT Signaling in Autoimmunity and Cancer. *Immunotarg. Ther.* **2025**, *14*, 523–554. [\[CrossRef\]](#) [\[PubMed\]](#)
259. Sohrabi, S.; Alipour, S.; Ghahramanipour, Z.; Masoumi, J.; Baradaran, B. STAT signaling pathways in immune cells and their associated mechanisms in cancer pathogenesis. *Bioimpacts* **2025**, *15*, 30030. [\[CrossRef\]](#) [\[PubMed\]](#)
260. Mukherjee, N.; Dart, C.R.; Amato, C.M.; Honig-Frand, A.; Lambert, J.R.; Lambert, K.A.; Robinson, W.A.; Tobin, R.P.; McCarter, M.D.; Coutts, K.L.; et al. Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. *J. Investig. Dermatol.* **2022**, *142*, 1912–1922 e1917. [\[CrossRef\]](#) [\[PubMed\]](#)
261. Lubrano, S.; Cervantes-Villagrana, R.D.; Arang, N.; Officer, A.; Adame-Garcia, S.R.; Cuesta-Margolles, G.; Aplin, A.E.; Gutkind, J.S. Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma. *J. Biol. Chem.* **2025**, *301*, 110712. [\[CrossRef\]](#) [\[PubMed\]](#)
262. Miller, M.; Schoenfield, L.; Abdel-Rahman, M.; Cebulla, C.M. Is Uveal Melanoma a Hormonally Sensitive Cancer? A Review of the Impact of Sex Hormones and Pregnancy on Uveal Melanoma. *Ocul. Oncol. Pathol.* **2021**, *7*, 239–250. [\[CrossRef\]](#) [\[PubMed\]](#)

263. Schoenfield, L.; Janse, S.; Kline, D.; Aronow, M.E.; Singh, A.D.; Craven, C.; Abdel-Rahman, M.; Cebulla, C.M. Estrogen Receptor Is Expressed in Uveal Melanoma: A Potential Target for Therapy. *Ocul. Oncol. Pathol.* **2021**, *7*, 303–310. [CrossRef] [PubMed]
264. Liu, K.; Zou, C.; Qin, B. The association between nuclear receptors and ocular diseases. *Oncotarget* **2017**, *8*, 27603–27615. [CrossRef] [PubMed]
265. Lucas, L.M.; Cullum, R.L.; Dwivedi, V.; Markham, J.A.; Woggerman, J.N.; Kelley, C.M.; Knerr, E.L.; Cook, L.J.; Lucas, H.C., 2nd; Waits, D.S.; et al. *ERBB4* drives the proliferation of *BRAF* WT melanoma cell lines. *medRxiv* **2023**. [CrossRef]
266. Lucas, L.M.; Cullum, R.L.; Markham, J.A.; Woggerman, J.N.; Dwivedi, V.; Mohamedelhassan, R.H.; Cook, L.J.; Kelley, C.M.; Knerr, E.L.; Kaufmann, D.P.; et al. *ERBB4* mutant alleles may drive *BRAF* WT melanomas. *medRxiv* **2023**. [CrossRef]
267. Dwivedi, V.; Lucas, L.M.; Cooke, R.; Davis, J.; Wilson, E.; Scott, M.; O'Daniel, K.; Dion, C.; Kerley, J.; Zelan, M.; et al. Human melanoma cell lines that possess wild-type *BRAF* alleles but are dependent on *ERBB4* and *ERBB2*. *bioRxiv* **2024**. [CrossRef]
268. Wilson, E.; Conway, A.; Riese, D.J., 2nd. Cancer Cell Line Encyclopedia Data Suggest that Ligands for *ERBB* Family Receptors May Drive *BRAF*-WT Melanomas. *bioRxiv* **2026**. [CrossRef]
269. MM28—CRL-3295. Available online: <https://www.atcc.org/products/crl-3295> (accessed on 29 March 2026).
270. MP41—CRL-3297. Available online: <https://www.atcc.org/products/crl-3297> (accessed on 29 March 2026).
271. MP46—CRL-3298. Available online: <https://www.atcc.org/products/crl-3298> (accessed on 16 June 2025).
272. Daniels, A.B.; Lee, J.E.; MacConaill, L.E.; Palescandolo, E.; Van Hummelen, P.; Adams, S.M.; DeAngelis, M.M.; Hahn, W.C.; Gragoudas, E.S.; Harbour, J.W.; et al. High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. *Investig. Ophthalmol. Vis. Sci.* **2012**, *53*, 6991–6996. [CrossRef] [PubMed]
273. Ma, D.; Niederkorn, J.Y. Role of epidermal growth factor receptor in the metastasis of intraocular melanomas. *Investig. Ophthalmol. Vis. Sci.* **1998**, *39*, 1067–1075.
274. Hurks, H.M.; Metzelaar-Blok, J.A.; Barthen, E.R.; Zwinderman, A.H.; De Wolff-Rouendaal, D.; Keunen, J.E.; Jager, M.J. Expression of epidermal growth factor receptor: Risk factor in uveal melanoma. *Investig. Ophthalmol. Vis. Sci.* **2000**, *41*, 2023–2027.
275. Scholes, A.G.; Hagan, S.; Hiscott, P.; Damato, B.E.; Grierson, I. Overexpression of epidermal growth factor receptor restricted to macrophages in uveal melanoma. *Arch. Ophthalmol.* **2001**, *119*, 373–377. [CrossRef] [PubMed]
276. Mallikarjuna, K.; Pushparaj, V.; Biswas, J.; Krishnakumar, S. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: An immunohistochemical study. *Curr. Eye Res.* **2007**, *32*, 281–290. [CrossRef] [PubMed]
277. Patel, S.P.; Kim, K.B.; Papadopoulos, N.E.; Hwu, W.J.; Hwu, P.; Prieto, V.G.; Bar-Eli, M.; Zigler, M.; Dobroff, A.; Bronstein, Y.; et al. A phase II study of gefitinib in patients with metastatic melanoma. *Melanoma Res.* **2011**, *21*, 357–363. [CrossRef] [PubMed]
278. Kassumeh, S.; Arrow, S.; Kafka, A.; Luft, N.; Priglinger, S.G.; Wolf, A.; Eibl-Lindner, K.; Wertheimer, C.M. Pharmacological drug screening to inhibit uveal melanoma metastatic cells either via EGF-R, MAPK, mTOR or PI3K. *Int. J. Ophthalmol.* **2022**, *15*, 1569–1576. [CrossRef] [PubMed]
279. NCT03775525: Study Evaluating GZ17-6.02 in Patients with Advanced Solid Tumors or in Combination with Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (GEN602). Available online: <https://clinicaltrials.gov/study/NCT03775525> (accessed on 18 July 2026).
280. Booth, L.; Roberts, J.L.; Spasojevic, I.; Baker, K.C.; Poklepovic, A.; West, C.; Kirkwood, J.M.; Dent, P. GZ17-6.02 kills PDX isolates of uveal melanoma. *Oncotarget* **2024**, *15*, 328–344. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.